Introduction {#s1}
============

Eukaryotic translation initiation is an intricate process that ensures accurate selection and decoding of the mRNA start codon. Initiation generally occurs through the scanning mechanism, which can be divided into the following discrete steps: (1a) 43S preinitiation complex (PIC) formation on the small (40S) ribosomal subunit by recruitment of methionyl initiator tRNA Met-tRNA~i~^Met^ in a ternary complex (TC) with GTP-bound eukaryotic initiation factor 2 (eIF2), facilitated by 40S-bound eIFs −1, −1A, −3, and −5; (1b) mRNA activation by binding of the eIF4F complex to the 7-methylguanosine capped 5' end; (2) 43S PIC attachment to the mRNA 5' end; (3) Scanning of the mRNA 5' untranslated region (UTR) by the PIC for a start codon in good sequence context; (4a) Start codon selection by Met-tRNA~i~^Met^ to form the 48S PIC; (4b) irreversible hydrolysis of GTP in the ternary complex, accompanied by release of eIF1 and its replacement on the 40S subunit by the eIF5 N-terminal domain; and (4 c) release of eIF2-GDP and eIF5 and recruitment of 60S subunit joining factor eIF5B by eIF1A; (5) Dissociation of eIF1A and eIF5B and joining of the 60S subunit to form the 80S initiation complex ([@bib18]; [@bib17]).

The eIF4F complex, which stimulates 43S PIC recruitment to mRNA, comprises eIF4E, eIF4A, and eIF4G. The eIF4E (encoded by the *CDC33* gene in yeast) is a 24 kDa protein that binds directly to the 5' cap of the mRNA. eIF4A (encoded by *TIF1* and *TIF2* genes in yeast) is a 44 kDa DEAD-box RNA helicase thought to resolve mRNA structures that impede PIC attachment or scanning. eIF4G1 (encoded by *TIF4631* in yeast) is a 107 kDa scaffold protein harboring binding sites for RNA (named RNA1, RNA2, RNA3), the two other eIF4F components (eIF4E and eIF4A), and the poly(A) binding protein (PABP), hence promoting formation of a circular 'closed-loop' messenger ribonucleoprotein (mRNP). eIF4G can also interact with eIF3 (in mammals) or eIF5 (in yeast) to facilitate 43S PIC recruitment to the mRNA. eIF4G1 has a paralog, eIF4G2 (encoded by *TIF4632* in yeast), which can make similar contacts with RNA and initiation factors and thereby promote initiation ([@bib9]). The functions of these canonical eIF4F components have been studied in considerable detail ([@bib18]; [@bib17]).

Recently, other DEAD-box RNA helicases besides eIF4A have been implicated in PIC attachment and scanning, including yeast Ded1 (homologous to Ddx3 in humans). Ded1 is an essential protein that stimulates bulk translation in vivo ([@bib8]; [@bib10]), and is especially important for translation of a large subset of yeast mRNAs characterized by long, structured 5' UTRs. Many such Ded1-hyperdependent mRNAs, identified by 80S ribosome footprint profiling of *ded1* mutants ([@bib27]), were shown recently to require Ded1 in vivo for efficient 43S PIC attachment or subsequent scanning of the 5'UTR using the technique of 40S subunit profiling ([@bib28]). Employing a fully reconstituted yeast translation initiation system, we further showed that Ded1 stimulates the rate of 48S PIC assembly on all mRNAs tested, but confers greater stimulation of Ded1-hyperdependent versus Ded1-hypodependent mRNAs (as defined by 80S ribosome profiling) in a manner dictated by stable stem-loop secondary structures in the 5'UTRs of the hyperdependent group ([@bib15]). Ded1 cooperates with its paralog Dbp1 in stimulating translation of a large group of mRNAs in vivo, and Dbp1 functions similarly to Ded1 in stimulating 48S PIC assembly in the yeast reconstituted system ([@bib28]).

In addition to its canonical DEAD box helicase region comprised of two RecA-like domains, Ded1 contains additional N-terminal and C-terminal domains (NTD, CTD) ([Figure 1A](#fig1){ref-type="fig"}) that are not well conserved in amino acid sequence even within the subfamily comprised of Ded1 and mammalian Ddx3 helicases; and are thought to be largely unstructured ([@bib30]). Distinct N-terminal and C-terminal extensions found immediately flanking the helicase core (NTE, CTE in [Figure 1A](#fig1){ref-type="fig"}) are relatively more conserved in the Ded1/Ddx3 subfamily, and at least for Ddx3, have partially defined structures and enhance the unwinding activity of the helicase core in vitro ([@bib12]). Ded1 can interact in vitro with all three subunits of eIF4G, binding to the C-terminal RNA3 domain of eIF4G via the CTD, and interacting with eIF4A via the NTD ([@bib16]; [@bib29]; [@bib13]). Interaction of eIF4A with the Ded1-NTD stimulates the ability of purified Ded1 to unwind model RNA duplexes, whereas Ded1 interaction with eIF4G decreases the rate of RNA unwinding while increasing Ded1 affinity for RNA in vitro ([@bib13]). Recently, we showed that the ability of Ded1 to stimulate 48S PIC formation in the reconstituted yeast system is impaired by elimination of either the Ded1-NTD, the Ded1-CTD, or the RNA2 or RNA3 domains of eIF4G1, with correlated defects for several mRNAs on removing the Ded1-CTD or eIF4G1 RNA3 domains that mediate Ded1/eIF4G1 interaction. These findings provided functional evidence that Ded1 association with the eIF4F subunits eIF4G and either eIF4A or eIF4E enhances Ded1 stimulation of 48S PIC assembly on native mRNAs ([@bib15]). It has been proposed that the majority of Ded1 exists in a stoichiometric complex with eIF4F in yeast cells ([@bib13]).

![eIF4A and eIF4E interact primarily with the Ded1 N-terminus in vitro.\
(**A**) Schema of in vitro synthesized Ded1 variants, either full length (FL), lacking either the N-terminal domain (NTD) residues 2--92 (ΔN), C-terminal domain (CTD) residues 562--604 (ΔC), or both (ΔNΔC), used in GST pull-down assays. All derivatives contain the entire N- (NTE) and C-terminal (CTE) extensions and the two RecA domains (DEAD~C~ and HELIC~C~) responsible for RNA helicase activity. (**B**) The Ded1 NTD is required for strong binding to GST-tagged eIF4A and eIF4E. The amounts of \[^35^S\]-labeled FL or truncated Ded1 proteins, visualized by fluorography (*upper panel*), present in the reactions (Input) or pulled down by GST, GST-eIF4A, or GST-eIF4A (visualized by Coomassie Blue staining, *lower panel*). (**C--D**) Quantification of the binding reactions for GST-eIF4A (**C**) or GST-eIF4E (**D**) by ImageJ analysis of fluorograms as in (**B**) from five replicate pull-down assays, expressing the amounts detected in the pull-downs as the percentages of input amounts. Individual dots show results of the replicates and bar heights give the mean values. n.s: not significant; \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001.](elife-58243-fig1){#fig1}

There is evidence that the Ded1-CTD/eIF4G interaction promotes Ded1 stimulation of translation in cell extracts, and also the ability of Ded1, when highly overexpressed in cells, to repress translation and promote formation of P-bodies---cytoplasmic granules that function in storage or decay of translationally silenced mRNA. However, the in vivo importance of the Ded1 CTD in stimulating translation at native levels of Ded1 expression is unclear, as its elimination does not affect cell growth on nutrient-replete medium at low temperatures where *ded1* mutations generally have the strongest phenotypes ([@bib16]). Instead, recent results indicate a role for the Ded1 CTD in down-regulating translation under conditions of reduced activity of the TORC1 protein kinase, which might entail increased degradation of eIF4G ([@bib5]). In contrast, the N-terminal region of Ded1 is clearly important for WT cell growth ([@bib16]; [@bib12]; [@bib13]). There is also limited evidence that eIF4A binding to this region is functionally important in vivo, based on the finding that eIF4A overexpression can mitigate the growth phenotypes of a *ded1* allele with mutations in multiple domains, but not one only lacking the N-terminal 116 residues that encompass the eIF4A interaction site ([@bib13]). However, this ΔNTD~1-116~ truncation might remove other functional determinants besides the eIF4A binding site that cannot be rescued by eIF4A overexpression, including a portion of the conserved NTE that enhances unwinding in vitro ([@bib12]). Although Ded1 contains an 8-amino acid segment with similarity to a sequence in mammalian Ddx3 shown to bind eIF4E ([@bib31]), and mutations in this Ded1 segment confer slow-growth phenotypes in yeast ([@bib16]; [@bib29]), it was not shown that eIF4E binds to the Ded1 NTD nor requires the conserved motif for this interaction. As the binding determinants for eIF4E in Ded1 have not been identified, it is also unclear whether eIF4E interaction with Ded1 is physiologically important.

In this study, we set out to pinpoint the binding sites for eIF4A and eIF4E in the Ded1 NTD, which were not currently known, and to establish the importance of each individual interaction in promoting Ded1's ability to stimulate translation of Ded1-hyperdependent mRNAs in vivo. We have mutationally dissected Ded1 N-terminal residues extending up to the conserved NTE and identified specific amino acids whose substitution impaired Ded1 binding to recombinant eIF4A or eIF4E in vitro, which delineated non-overlapping NTD residues required for interaction with each factor. We could then demonstrate that NTD substitutions that selectively disrupt its association with eIF4A or eIF4E in vitro also impair association of Ded1 with native eIF4A or eIF4E in vivo, and diminish Ded1's ability to promote cell growth, bulk translation initiation, and translation of Ded1-dependent reporter mRNAs harboring defined stem-loop (SL) structures in their 5'UTRs, in yeast cells. We further showed that selectively disrupting Ded1 interactions with eIF4E or eIF4A by these NTD substitutions impaired Ded1 acceleration of 48S PIC assembly on a SL-containing reporter mRNA in the yeast reconstituted system. We provided additional genetic evidence that the key Ded1 NTD residues promote translation in vivo specifically by mediating interaction with eIF4A or eIF4E, and that this constitutes the critical in vivo function of the entire Ded1 NTD. Finally, we found that the Ded1 CTD becomes crucial for robust cell growth and translation initiation in vivo when Ded1's contacts with eIF4A or eIF4E are absent and its association with eIF4F must rely on Ded1-CTD interactions with eIF4G. Together, our results establish that the individual interactions of Ded1 with eIF4A, eIF4E and eIF4G that stabilize the eIF4F·Ded1 complex all promote Ded1 function in stimulating translation initiation in nutrient-replete yeast cells.

Results {#s2}
=======

Evidence that eIF4A and eIF4E both interact with the Ded1-NTD in vitro {#s2-1}
----------------------------------------------------------------------

Discrete binding determinants for eIF4A and eIF4E within the yeast Ded1 protein were unknown, which has made it difficult to assess the physiological importance of each interaction in vivo. To identify amino acids important for each interaction, we assayed binding of bacterially expressed glutathione-S-transferase (GST) fusions made to full-length yeast eIF4A1 or eIF4E to in vitro translated \[^35^S\]-labeled Ded1 polypeptides, beginning with full-length (FL) Ded1 (amino acids 1--604) and truncated Ded1 variants lacking NTD residues 2--92 (ΔN~2-92~), CTD residues 562--604 (ΔC~562-604~), or both domains (ΔNC) ([Figure 1A](#fig1){ref-type="fig"}). The labeled Ded1 polypeptides recovered with GST-eIF4A, GST-eIF4E, or GST alone on glutathione-agarose beads were resolved by SDS-PAGE, with the result that the FL Ded1 polypeptide bound to both GST-eIF4A and GST-eIF4E, but not GST alone ([Figure 1B](#fig1){ref-type="fig"}, lanes 9 and 13 vs. 5), confirming specific, separate interactions of Ded1 with both eIF4A and eIF4E. These and all subsequent pull-down assays included RNAase treatment to insure that the interactions were not bridged by RNA.

The amounts of bound Ded1 polypeptides were quantified and normalized to the input amounts for each reaction, and mean percentages of the input amounts that bound to GST-eIF4A or GST-eIF4E in replicate pull-down experiments were compared between FL Ded1 and the three truncated Ded1 variants. For GST-eIF4A, binding of the ΔC~562-604~ and FL Ded1 polypeptides were comparable, whereas drastically reduced amounts of the ΔN~2-92~ and ΔNC variants were bound ([Figure 1C](#fig1){ref-type="fig"}). These results support previous findings that eIF4A interacts specifically with the Ded1 NTD ([@bib13]). Eliminating the NTD reduced Ded1 binding to GST-eIF4E as well, although binding was also reduced to a lesser extent by deleting the Ded1 CTD ([Figure 1D](#fig1){ref-type="fig"}). Importantly, however, comparing the results for ΔNC and ΔN~2-92~ revealed that the low-level binding conferred by ΔN~2-92~ was not significantly diminished by ΔC~562-604~, whereas ΔN~2-92~ exacerbated the moderate binding defect of ΔC~562-604~ ([Figure 1D](#fig1){ref-type="fig"}). These results suggest that the Ded1 NTD is considerably more important than the CTD for eIF4E binding, and provide the first evidence that eIF4E binds directly to the yeast Ded1 NTD.

Ded1 has also been reported to interact through its C-terminus with eIF4G ([@bib13]; [@bib16]; [@bib29]). We verified this interaction under the conditions of our binding assay by determining that the ΔC~562-604~ truncation was sufficient to abolish binding by \[^35^S\]-labeled Ded1 to a GST-eIF4G fusion expressed in bacteria ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, lanes 10 and 12). Thus, the Ded1 CTD is essential for binding to eIF4G but is either dispensable or relatively unimportant for interactions with eIF4A or eIF4E, respectively.

eIF4A and eIF4E binding determinants in the Ded1 NTD are distinct and non-overlapping {#s2-2}
-------------------------------------------------------------------------------------

To identify specific Ded1 residues critical for binding eIF4A and eIF4E in vitro, we generated \[^35^S\]-labeled variants of the FL Ded1 polypeptide containing clustered alanine substitutions, or in one case a deletion, of ten blocks of conserved amino acids located throughout the NTD ([Figure 2A](#fig2){ref-type="fig"}). While the main consideration for sequence conservation was similarity among other *Saccharomycetaceae* species ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}), most of these clusters include residues also conserved in higher eukaryotes ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Using the same GST pull-down assay as above, we observed that substituting Ded1 NTD residues 21--27, 29--35 and 51--57 conferred the greatest reductions in binding to GST-eIF4A ([Figure 2B](#fig2){ref-type="fig"}, cols. 5, 6, 8, bars in green hues), whereas residues 59--65 and 83--89 appear to be most important for binding to GST-eIF4E ([Figure 2C](#fig2){ref-type="fig"}, cols. 9,11, orange hues). These findings suggested that the critical binding determinants for eIF4A and eIF4E are located in adjacent, non-overlapping segments of the Ded1 NTD, located within residues 21--57 for eIF4A and within residues 59--89 for eIF4E.

![GST-eIF4A and GST-eIF4E bind to distinct non-overlapping segments of the Ded1 NTD.\
(**A**) WebLogo of amino acid sequence conservation in the Ded1 NTD among *Saccharomyces* species *S. cerevisiae, S. arboricola, S. kudriavzevii, S. bayanus, S. boulardii, S. mikatae, S. paradoxus,* and *S. pastorianus*. The blocks of residues chosen for clustered alanine substitutions, or in one case deletion (Δ40), of every residue in the block are underlined and labeled by the residue positions. The locations of segments implicated in binding to eIF4A or eIF4E by results in (**B--C**) are indicated. (**B**) Multiple segments in the N-terminal portion of the Ded1-NTD promote binding to GST-eIF4A. Results of pull-down assays using GST-eIF4A and the indicated FL or mutant Ded1 proteins, determined as in [Figure 1B--C](#fig1){ref-type="fig"} except using four replicates. Differences between mean values were analyzed with an unpaired students's t-test. n.s.: not significant, \*: p\<0.05, \*\*: p\<0.01. Shades of green indicate statistically significant decreases in mean values versus the FL construct, with darker shades indicating greater defects. (**C**) Multiple segments in the C-terminal portion of the Ded1-NTD promote binding to GST-eIF4E. Results of pull-down assays using GST-eIF4E and the indicated FL or mutant Ded1 proteins, determined as in [Figure 1B--C](#fig1){ref-type="fig"} except using four replicates. Shades of orange indicate statistically significant decreases in mean values versus the FL construct.](elife-58243-fig2){#fig2}

To determine whether the non-contiguous binding determinants within each of these two intervals make additive contributions to binding eIF4A or eIF4E, we examined additional variants harboring combined substitutions of two different clusters. Whereas combining the contiguous substitutions 21--27 and 29--35 produced no further reduction in binding to GST-eIF4A compared to the single substitutions ([Figure 2B](#fig2){ref-type="fig"}, cols. 13 vs. 5 and 6), an additive reduction in binding was observed on combining the non-contiguous substitutions 21--27 and 51--57 ([Figure 2B](#fig2){ref-type="fig"}, cols. 14 vs. 5 and eight and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, cols. 5 vs. 1 and 2), which was comparable in its effect to deleting the entire (ΔNTD~2-92~) on binding to GST-eIF4A ([Figure 2B](#fig2){ref-type="fig"}, cols. 2 and 14, dark green hues). In contrast, combining the non-contiguous substitutions that individually impaired eIF4E binding produced reductions in binding by the 59-65/83-89 variant indistinguishable from those generated by the single substitutions ([Figure 2C](#fig2){ref-type="fig"}, cols. 16 vs. 9 and 11 and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, cols. 12 vs. 9 and 10). It is noteworthy that the two double substitutions that impair binding to GST-eIF4A (21-27/29-35 and 21-27/51-57) had little or no effect on binding to GST-eIF4E ([Figure 2B--C](#fig2){ref-type="fig"}, cols. 13--14), and that the double substitution 59-65/83-89 strongly reduced binding to GST-eIF4E with no significant effect on binding to GST-eIF4A ([Figure 2B--C](#fig2){ref-type="fig"}, col. 16). These last findings support the notion that the binding determinants for eIF4A and eIF4E are segregated into non-overlapping adjacent segments of the NTD.

Combining substitution 51--57 that selectively impairs binding to GST-eIF4A with the adjacent substitution 59--65 that selectively impairs binding to GST-eIF4E produced a binding defect to GST-eIF4E indistinguishable from that given by 59--65 alone ([Figure 2C](#fig2){ref-type="fig"}, cols. 15 vs. 8 and 9), supporting our conclusion that the binding determinants for eIF4E do not extend upstream into the region that binds eIF4A. However, the 59--65 substitution appeared to suppress the eIF4A binding defect of the adjacent upstream substitution 51--57 in the 51-57/59-65 variant ([Figure 2B](#fig2){ref-type="fig"}, cols. 15 vs. 8 and 9). One way to explain this 'context dependence' of the 51--57 substitution would be to propose that the residues in segment 59--65 that mediate eIF4E binding also antagonize binding of eIF4A to the contiguous segment 51--57 segment, such that their removal lessens the requirement for the eIF4A binding determinants in the 51--57 segment. Consistent with this possibility, we found that the 59--65 substitution did not suppress the stronger binding defect conferred by combining the non-contiguous substitution 21--27 with 51--57 in a 21-27/51-57/59-65 triple mutant ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, col. eight vs. col. 6). Regardless of the explanation, the 21-27/51-57 and 59-65/83-89 double substitutions provide Ded1 variants that selectively impair binding to eIF4A or eIF4E for our subsequent in vivo analysis.

The Ded1 NTD is highly unstructured ([@bib12]) and harbors RGG/RG motifs ([@bib25]). To examine whether these motifs contribute to Ded1 interactions with eIF4A or eIF4E, we examined substitutions R27A, G28A, and R51A within the presumptive eIF4A-binding region identified above. Interestingly, R27A impaired binding to GST-eIF4A to the same extent observed on substituting the entire cluster 21--27 in which R27 resides, whereas G28A and R51A had no effect ([Figure 2---figure supplement 4B](#fig2s4){ref-type="fig"}). This finding is in accordance with the fact that R27 is highly conserved in the family *Saccharomycetaceae,* as well as in animals ([Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}), whereas, G28 and R51 are not. In contrast, despite its strong sequence conservation, Ala substitution of R62 within the region implicated in eIF4E binding had no significant effect on binding to GST-eIF4E ([Figure 2---figure supplement 4B](#fig2s4){ref-type="fig"}, *right* graph); although we note that the adjacent residue at position 61 is also an Arg in *S. cerevisiae.*

We further reasoned that because the Ded1 NTD is intrinsically unstructured, its hydrophobic and/or aromatic residues may be solvent-exposed and available for protein-protein interactions. Accordingly, we examined substitutions of five Phe or Tyr residues located within the NTD blocks of residues implicated above in binding to eIF4A or eIF4E. Strikingly, substituting each of the aromatic residues Y65 and W88 reduced binding to GST-eIF4E to the same extent observed for Ala substitutions of the entire corresponding segments 59--65 and 83--89, respectively ([Figure 2---figure supplement 4C](#fig2s4){ref-type="fig"}). By contrast, the Y21A and F56A/F57A substitutions within the eIF4A binding determinants 21--27 and 51/57, respectively, had no significant effect on binding to GST-eIF4A ([Figure 2---figure supplement 4C](#fig2s4){ref-type="fig"}). Together, these last findings reinforce the identification of segments 59--65 and 83--89 as binding determinants for eIF4E, and further suggest that aromatic residues Y65 and W88 within these segments might mediate key hydrophobic interactions with eIF4E. Although Y65 is not highly conserved, W88 is invariant among the eukaryotic species we examined ([Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}).

Disruption of discrete binding determinants for eIF4A or eIF4E in the Ded1 NTD confers growth defects in vivo {#s2-3}
-------------------------------------------------------------------------------------------------------------

Having identified substitutions in the Ded1 NTD that selectively reduce Ded1 binding to GST-eIF4A or GST-eIF4E in vitro, we addressed next whether these substitutions reduce Ded1 function in vivo. We began by asking whether the Ded1 NTD substitutions confer synthetic growth defects when combined with the temperature-sensitive (Ts^-^) *ded1-952* mutation, which strongly impairs growth at 37°C ([@bib27]) but confers only a moderate slow-growth (Slg^-^) phenotype at 34°C ([Figure 3B](#fig3){ref-type="fig"}, rows 1--2) when introduced as a plasmid-borne Myc~13~-tagged allele expressed from the native promoter (henceforth *ded1-ts,* [Figure 3A](#fig3){ref-type="fig"}) in a strain deleted for chromosomal *DED1*. Compared to *ded1-ts* alone, the *ded1-ts* alleles also containing the *21--27* or *51--57* mutations shown above to impair eIF4A binding in vitro conferred stronger Slg^-^ phenotypes at 34°C, with a slightly greater defect when the two mutations were combined within *ded1-ts-21-27/51-57* ([Figure 3B](#fig3){ref-type="fig"}, 34°C, rows 6--9). Similar findings were made for the *59--65, 83--89,* and *59-65/83-89* mutations that selectively impair eIF4E binding to Ded1 in vitro ([Figure 3B](#fig3){ref-type="fig"}, row 6 vs. 10--12), except that the reductions in growth were less pronounced than observed for the *21--27* and *21-27/51-57* mutations that impair eIF4A binding ([Figure 3B](#fig3){ref-type="fig"}, cf. rows 10--12 vs. 7 and 9). In contrast, the *14--20* and *Δ40--47* mutations that did not affect Ded1 binding to eIF4A or eIF4E in vitro also conferred no Slg^-^ in combination with *ded1-ts* in vivo. (The apparent suppression of the *ded1-ts* phenotype by *14--20* was not reproduced in independent transformants.) Western analysis showed that neither the double substitution *21-27/51-57* nor the quadruple substitution *21-27/51-57,59-65/83-89* reduced the steady-state level of the *ded1-ts* product ([Figure 3D](#fig3){ref-type="fig"}, lanes 5--7), indicating that they impair Ded1 function and not its expression.

![Clustered substitutions of Ded1 NTD residues that impair interaction with eIF4A or eIF4E in vitro confer growth defects in yeast.\
(**A**) Schematics of the myc~13~-tagged parental *DED1* and *ded1-ts* alleles, expressed from the native *DED1* promoter (*P~DED1~*) on a single copy (sc) plasmid, used to introduce NTD mutations described in [Figure 2A](#fig2){ref-type="fig"}. (**B**) Mutations substituting single or double binding determinants for eIF4A (*21-27; 51-57; 21-27/51-57*) or eIF4E (*59-65; 83-89; 59-65/83-89*) display synthetic temperature sensitivities with the *ded1-ts* allele of differing severity. Serial dilutions of yeast strains derived from yRP2799 by plasmid-shuffling containing the indicated derivatives of the *ded1-ts* (rows 2--12), or WT *DED1* allele (row 1), on sc *LEU2* plasmids (listed in [Table 3](#table3){ref-type="table"}) were spotted on synthetic complete medium lacking Leu (SC-Leu) and incubated at the indicated temperatures for 2-4d. (**C**) Disruption of eIF4A and eIF4E binding sites concurrently confers a severe growth defect comparable to that of NTD deletion *Δ2--90*. Yeast strains harboring the indicated derivatives of *DED1* (rows 1--5) or *ded1-ts* (rows 6--8) were analyzed as in (**B**). (**D**) Expression levels of the indicated mutants from (**B**) or (**C**) were assessed by Western analysis of WCEs extracted under denaturing conditions with TCA, using the indicated antibodies, following growth in SC-Leu at 18°C for *DED1* derivatives and 34°C for *ded1-ts* derivatives. Ded1/Hcr1 ratios of the indicated derivatives of the WT *DED1* or *ded1-ts* allele were obtained by ImageJ analysis of 3 independent experiments and are normalized to the corresponding parental allele's Ded1/Hcr1 ratios. This particular blot was atypical in suggesting a reduced level of the *ded1-ts-Δ2--90* product.](elife-58243-fig3){#fig3}

The single amino acid substitutions Y21A and R27A in the eIF4A binding region each conferred a Slg^-^ phenotype at 34°C in combination with *ded1-ts,* which for *R27A* was greater than that observed for *Y21A* and comparable to that given by the *21--27* clustered substitution that encompasses both single-residue substitutions ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, rows 5--6 vs. 2--3). These phenotypes correlate with the stronger eIF4A binding defect given by R27A versus Y21A, and with the similar binding defects observed for R27A and the 21--27 variant in vitro ([Figure 2---figure supplement 4B](#fig2s4){ref-type="fig"}). Although Y21A had little effect on Ded1 binding to eIF4A in vitro ([Figure 2---figure supplement 4B](#fig2s4){ref-type="fig"}), the residue is highly conserved ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) and, hence, might have a greater impact in vivo. The F56A/F57A substitutions in the 51--57 interval, which had no effect on GST-eIF4A binding in vitro ([Figure 2---figure supplement 4B](#fig2s4){ref-type="fig"}) also had no effect on cell growth in combination with *ded1-ts* ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, rows 2 and 7). The Y65A and W88A single residue substitutions in the respective 59--65 and 83--89 segments of the eIF4E binding region each conferred moderate Slg^-^ phenotypes in combination with *ded1-ts* indistinguishable from those given by the corresponding *59--65* and *83--89* clustered substitutions ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, rows 11--12 vs. 9--10). These last findings are in accordance with the defects in GST-eIF4E binding in vitro shown above for these single and clustered substitutions ([Figure 2---figure supplement 4C](#fig2s4){ref-type="fig"}). Taken together, the effects of single-residue and clustered NTD substitutions on Ded1 binding to GST-eIF4A or GST-eIF4E in vitro are generally well correlated with their effects on cell growth in combination with the *ded1-ts* allele, with relatively stronger growth defects associated with mutations that reduce Ded1 binding to eIF4A versus those conferring comparable reductions in Ded1 binding to eIF4E.

We also examined the effects of the NTD mutations on Ded1 function in the absence of the *ded1-ts* mutation, finding that the *21-27/51-57* double cluster mutation affecting eIF4A binding confers a cold-sensitive Slg^-^ phenotype, which is exacerbated on combining it with the *59-65/83-89* double cluster mutations that impair eIF4E binding in vitro ([Figure 3C](#fig3){ref-type="fig"}, rows 1--4). Interestingly, the latter quadruple mutation conferred a strong Slg^-^ phenotype comparable to that given by the *ded1-Δ2--90* deletion allele lacking nearly the entire NTD, both in otherwise WT *DED1* ([Figure 3C](#fig3){ref-type="fig"}, rows 4--5) and in the *ded1-ts* allele, which suggests that binding to eIF4A and eIF4E constitutes the key in vivo function of the Ded1 NTD. Again, Western analysis revealed that the double and quadruple substitutions, as well as the Δ2--90 NTD deletion, had little effect on Ded1 steady-state expression levels ([Figure 3D](#fig3){ref-type="fig"}, lanes 1--4).

Finally, we asked whether disrupting binding of the Ded1 NTD to eIF4A or eIF4E would reveal an impact on cell growth of eliminating the Ded1 CTD and its known interaction with eIF4G. Consistent with previous findings ([@bib16]), the CTD deletion that removes the C-terminal 43 residues of Ded1 (*ded1-ΔC*) confers no growth defect when the rest of Ded1 is intact. Importantly, however, the *ΔC* mutation exacerbates the cold-sensitive Slg^-^ phenotypes of all of the *ded1* mutations examined containing single- or double cluster substitutions in the NTD that impair binding to either eIF4A or eIF4E. While the exacerbation by *ΔC* is subtle for the *51--57, 59--65,* and *83--89* single-cluster mutations, it is pronounced for *21--27* and both double-cluster substitutions ([Figure 4A](#fig4){ref-type="fig"}, cf. adjacent rows). The exacerbation of the cold-sensitive growth phenotype of the NTD double-cluster mutations by *ΔC* occurred without reducing expression relative to the NTD variants with an intact CTD ([Figure 4B](#fig4){ref-type="fig"}, lanes 4--6). These findings are consistent with the idea that interaction of the Ded1 CTD with eIF4G is less critical for stabilizing the Ded1-eIF4E-eIF4A-eIF4G quaternary complex, activating Ded1 helicase function, or both, compared to the Ded1 NTD interactions with eIF4E and eIF4A; but that the importance of the CTD is increased when either the Ded1-eIF4E or Ded1-eIF4A interactions are impaired.

![The Ded1 CTD is important for robust cell growth when NTD interactions with eIF4A or eIF4E are compromised.\
(**A**) Rates of colony formation of strains derived from yRP2799 containing the indicated derivatives of the WT *DED1* allele were analyzed as in [Figure 3B](#fig3){ref-type="fig"}. (**B**) Western analysis of the indicated mutants from (**A**) conducted as in [Figure 3D](#fig3){ref-type="fig"}.](elife-58243-fig4){#fig4}

Evidence that discrete binding determinants in the Ded1 NTD are important for interactions with eIF4A and eIF4E in vivo {#s2-4}
-----------------------------------------------------------------------------------------------------------------------

Having identified eIF4A and eIF4E binding determinants in the Ded1 NTD in vitro and also demonstrating their contributions to Ded1 function in supporting cell growth, we sought next to demonstrate the importance of these interaction sites for Ded1 association with eIF4A or eIF4E in vivo using immunoprecipitation of myc-tagged Ded1 from yeast lysates. To this end, the *myc~13~*-tagged *ded1-ts* alleles containing the *21-27/51-57* or *59-65/83-89* double-cluster mutations, *ded1-ts* containing no other mutations, or empty vector were introduced into a *DED1* strain lacking the chromosomal genes encoding eIF4G1 and eIF4G2 and expressing HA-tagged eIF4G1 from a plasmid under the eIF4G2 promoter, and whole cell extracts (WCEs) were immunoprecipitated with anti-Myc antibodies. The eIF4A, eIF4E, and eIF4G1-HA all coimmunoprecipitated specifically with the myc~13~-tagged *ded1-ts* product, failing to be immunoprecipitated from the extract lacking a myc-tagged protein ([Figure 5](#fig5){ref-type="fig"}, rows 5--6), as expected for Ded1 interaction with eIF4F. The presence of mutations *21-27/51-57* in the *ded1-ts* allele, which impair Ded1 binding to GST-eIF4A in vitro ([Figure 2B](#fig2){ref-type="fig"}) reduced coimmunoprecipitation of the myc~13~-tagged product with native eIF4A, but not eIF4E or eIF4G1-HA from WCEs ([Figure 5](#fig5){ref-type="fig"}, rows 6--7). Moreover, mutations *59-65/83-89,* which reduced Ded1 binding to GST-eIF4E in vitro ([Figure 2C](#fig2){ref-type="fig"}), specifically impaired coimmunoprecipition of eIF4E with the myc~13~-tagged *ded1-ts/59-65/83-89* product ([Figure 5](#fig5){ref-type="fig"}, lanes 6 and 8). The results were unaffected by treating the immune complexes with RNAses A and T1 ([Figure 5](#fig5){ref-type="fig"}, lanes 9--12 vs. 5--8), suggesting that the interactions are not bridged by RNA. Thus, the binding determinants in the Ded1 NTD for eIF4A and eIF4E defined by in vitro pull-down assays with recombinant GST fusions to eIF4A or eIF4E are also crucial for association of native eIF4A or eIF4E with the *ded1-ts* product expressed at native levels in yeast cells. Because WT Ded1 is present in these cells, the reductions in eIF4E/eIF4A coimmunoprecipitation with the ded1-ts variants harboring NTD substitutions might have been intensified by competition with WT Ded1 for binding to eIF4F.

![Disrupting Ded1 NTD binding determinants for eIF4A or eIF4E selectively impair association of the *ded1-ts* product with native eIF4A or eIF4E in yeast WCEs.\
Transformants of strain H4436 (expressing HA-tagged eIF4G1 and lacking eIF4G2) harboring the indicated derivatives of (myc~13~-tagged) *ded1-ts* were cultured in SC-Leu-Trp medium and WCEs prepared under non-denaturing conditions (lanes 1--4) were immunoprecipitated with anti-myc antibodies (lanes 5--12). Aliquots corresponding to 5% of the WCEs and 50% of the resulting immune complexes, either without treatment (lanes 5--8) or following 30 min treatment with RNAse A/T1 at room temperature (lanes 9--12), were subjected to Western analysis with the indicated antibodies.](elife-58243-fig5){#fig5}

Our findings that the NTD substitutions selectively reduced association of the *ded1-ts* product with only eIF4E or eIF4A versus all three eIF4F subunits might indicate that Ded1 exists predominantly in binary complexes with each of the subunits of eIF4F; however, this would be odds with the expectation that the majority of Ded1 is associated with eIF4F in cells, based on estimates of the binding constant for Ded1 association with eIF4F and the cellular concentrations of these factors ([@bib13]). Rather, it seems plausible that weakening the association of Ded1 with eIF4E leads to a specific reduction in eIF4E coimmunoprecipitation with ded1-ts owing to dissociation of eIF4E from the scaffold subunit eIF4G during the extensive washing steps involved in the experiment, notwithstanding the known stable interaction of eIF4E with eIF4G ([@bib19]). The relatively lower affinity of yeast eIF4A for eIF4G ([@bib19]; [@bib23]) makes this explanation even more likely for the selective loss of eIF4A association with mutated ded1-ts; although the existence of Ded1-eIF4A binary complexes in vivo has also been predicted ([@bib13]).

Genetic evidence that eliminating interactions with eIF4A or eIF4E is responsible for growth defects conferred by substituting Ded1-NTD binding determinants {#s2-5}
------------------------------------------------------------------------------------------------------------------------------------------------------------

We sought next to provide evidence that eliminating the binding determinants for eIF4A or eIF4E in the Ded1 NTD confer growth defects owing to loss of the specific interaction with eIF4A or eIF4E, respectively. We reasoned that if a Ded1 NTD substitution confers a growth defect, but can still partially interact with its binding partner, then overexpression of the partner should reinstate the interaction by mass action and rescue normal cell growth. If however the Ded1 mutant cannot bind to the partner at all, then overexpressing the latter might have little effect on cell growth ([Figure 6A](#fig6){ref-type="fig"}). To test this prediction, we overexpressed eIF4A1 from a high-copy (hc) *TIF1* plasmid in the panel of *ded1-ts* mutants with single or double cluster substitutions in the eIF4A binding region and measured growth rates by cell-spotting assays. eIF4A overexpression mitigated the Slg^-^ phenotypes at 34°C of the *21--27, 29--35,* and *51--57* single-cluster mutations, and also the *21-27/29-35* double cluster mutations ([Figure 6B](#fig6){ref-type="fig"}, rows 3--10, cf. adjacent rows), all of which conferred partial reductions in Ded1 binding to GST-eIF4A in vitro ([Figure 2B](#fig2){ref-type="fig"}), consistent with restored interaction of Ded1-eIF4A association by mass action. Importantly however, eIF4A overexpression did not mitigate the stronger Slg^-^ phenotype conferred by the *ded1-ts,21-27/51-57* double-cluster mutation ([Figure 6B](#fig6){ref-type="fig"}, rows 11--12), which reduced binding to GST-eIF4A to the low level conferred by the ΔN~2-92~ deletion that removes the entire eIF4A binding domain ([Figure 2B](#fig2){ref-type="fig"}). Nor did eIF4A overexpression mitigate the Slg^-^ phenotype conferred by the *59-65/83-89* mutations that selectively impair binding to eIF4E ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), supporting the interpretation that suppression of the other NTD mutations that partially impair eIF4A binding results from restoration of Ded1-eIF4A association by mass action ([Figure 6A](#fig6){ref-type="fig"}). Western analysis verified that eIF4A was overexpressed similarly in all of the *ded1* mutants ([Figure 6C](#fig6){ref-type="fig"}). These findings support the idea that Ded1 substitutions in the eIF4A-binding region of the NTD confer growth defects in vivo owing to impaired association with eIF4A in cells.

![Evidence that Ded1-NTD binding determinants of eIF4A promote cell growth by enhancing eIF4A association.\
(**A**) Schema summarizing expected outcomes for Ded1-eIF4A association based on mass action on overexpressing eIF4A (grey circles) in cells containing different *ded1-ts* proteins (dark grey circles), as follows: (i) otherwise WT; (ii) a *ded1-ts* derivative lacking a single binding determinant (single star) that only reduces binding to eIF4A, or (iii) a *ded1-ts* derivative lacking two binding determinants (double star) that essentially abolishes eIF4A binding. Ded1-eIF4A association depicted by overlapping the circles. (**B**) Derivatives of strain yRP2799 containing the indicated *ded1-ts* alleles harboring hc*TIF1* plasmid pBAS3432 or empty vector were examined for rates of colony formation at the indicated temperatures as in [Figure 3B](#fig3){ref-type="fig"}. (**C**) Western blot analysis of the strains in (**B**) conducted as in [Figure 3D](#fig3){ref-type="fig"} using the indicated antibodies.](elife-58243-fig6){#fig6}

When we subjected the *ded1-ts* alleles containing single- or double cluster mutations in the eIF4E binding region to a similar analysis by overexpressing eIF4E from a hc *CDC33* plasmid, we saw a uniform, modest exacerbation of growth defects for all strains (not shown), which may indicate that eIF4E overexpression is toxic for yeast. Instead, we exploited the fact that overexpressing WT *DED1* can mitigate the growth defects conferred by the chromosomal eIF4E mutant allele *cdc33-1* ([@bib10]). In agreement with this, we found that overexpressing either WT *DED1* or the *ded1-21-27/51-57* allele defective for eIF4A binding from a hc plasmid increased the growth rate of *cdc33-1* cells ([Figure 7A](#fig7){ref-type="fig"}, rows 3--4 vs. 1. Importantly, however, the hc *ded1-59-65/83-89* allele, defective for eIF4E binding in vitro, had no effect on growth of the mutant cells ([Figure 7A](#fig7){ref-type="fig"}, row 5 vs. 1). Western analysis verified that the mutant and WT *ded1* alleles were overexpressed similarly in the *cdc33-1* mutant ([Figure 7B](#fig7){ref-type="fig"}). These findings have two important implications. First, they provide strong evidence that the *ded1-59-65/83-89* mutation impairs both a physical and functional interaction between Ded1 and eIF4E in cells. Second, they imply that overexpressing Ded1 partially suppresses the *cdc33-1* mutation by enhancing interaction of the *cdc33-1* product with Ded1 by mass action, presumably increasing the concentration of the eIF4F·Ded1 complex in which Ded1 functions most efficiently, rather than indirectly compensating for a reduction in eIF4F function (that should occur for all *ded1* alleles).

![Evidence that Ded1-NTD binding determinants of eIF4E promote cell growth by enhancing eIF4E association.\
(**A**) Transformants of *cdc33-1* mutant F696 harboring empty vector YEplac195, hc*CDC33* plasmid (p3351), or hc plasmids with the indicated WT (p4504) or mutant (pSG48 or pSG49) *DED1* alleles were examined for rates of colony formation at the indicated temperatures as in [Figure 3B](#fig3){ref-type="fig"}. (**B**) Western blot analysis of the strains in (**A**) conducted as in [Figure 3D](#fig3){ref-type="fig"} using the indicated antibodies.](elife-58243-fig7){#fig7}

Disruption of Ded1-eIF4A or eIF4E interactions impairs translation in vivo {#s2-6}
--------------------------------------------------------------------------

We next investigated changes in bulk translation initiation upon disruption of Ded1-eIF4A or Ded1-eIF4E interactions by Ded1 NTD mutations, examining first the effects on total polysome assembly. Cells were treated with cycloheximide just prior to harvesting to prevent polysome run-off during isolation, and polysomes were resolved from 80S monosomes, free 40S and 60S subunits, and free mRNPs by sedimentation through sucrose density gradients. Both the *ded1-ts,21-27/51-57* and *ded1-ts,59-65/83-89* mutations, impairing Ded1 interactions with eIF4A or eIF4E, respectively, reduced the ratio of polysomes to monosomes (P/M), indicating a reduction bulk translation initiation, which was not significantly greater for one mutation versus the other ([Figure 8A](#fig8){ref-type="fig"}).

![Disruption of Ded1 NTD interactions with eIF4A or eIF4E confer bulk and mRNA-specific translation defects in vivo.\
(**A**) Polysome profiling of derivatives of strain yRP2799 containing the indicated *ded1-ts* alleles lacking binding determinants for eIF4A (ii) or eIF4E (iii) exhibit a decrease in bulk polysome assembly compared to the parental *ded1-ts* strain (**i**). Strains were cultured in SC-Leu medium after shifting from 30°C to 36°C for 3 hr, and WCE extracts were resolved by velocity sedimentation and scanned at 260 nm. The mean ratios of polysomes to monosomes (P/M) determined from three replicate WCEs are indicated. The mean P/M ratios for each mutant differ significantly from the WT mean ratio (both p-values\<0.002), but not from each other (p=0.08). Parallel analysis of isogenic *DED1^+^* cells revealed, as expected, a significantly greater P/M ratio (3.90 + / - 0.11) compared to that shown in the figure for *ded1-ts* (2.39 + / - 0.10). (**B**) Schema of the reporter constructs employed to interrogate Ded1-dependent translation in vivo, containing the *RPL41A* promoter and 3'UTR containing derivatives of the *RPL41A* 5'UTR harboring 23 tandem repeats of CAA nucleotides (nt) and designed to be largely unstructured (No SL, pFJZ342), or additionally containing a stem-loop insertion (of predicted ΔG of −3.7kcal/mol) located 55 nt from the 5'end (Cap-distal SL, pFJZ623), or a SL (of predicted ΔG of −8.1kcal/mol) at seven nt from the 5'end (Cap-proximal SL, pFJZ669). (**C**) Transformants of strains derived from yRP2799 with the indicated *ded1-ts* alleles and reporter constructs from (**B**) were cultured in SC-Leu at 34°C for two doublings and mean specific luciferase activities were determined from three independent transformants and normalized to that obtained for the reporters in the *ded1-ts* parental strain, which were set to unity.\*: Significant differences in mean values compared to *ded1-ts*; †: compared to *ded1-ts/51--57*; \#: compared to *ded1-ts/59--65*; §: compared to *ded1-ts/83--89*, as indicated by a p-value of \<0.05 in an unpaired student's t-test. The effects of substitutions in impairing binding to eIF4A, eIF4E, or neither protein (Control), are indicated at the bottom. (**D**) Distributions of *ACT1* mRNA (i), or Cap-proximal SL reporter mRNA (ii), across sucrose gradients following velocity sedimentation of WCEs of strains from (**C**) containing the indicated *ded1* alleles and the Cap-proximal SL reporter. qRT-PCR was conducted on total RNA purified from each fraction using primers specific for *ACT1* or *FLUC* mRNA, and the abundance of each transcript was normalized to that of a set of 'spike-in' controls and plotted as a fraction of the total normalized abundance in the entire gradient. The mean values and S.E.M.s determined from three replicate gradients are plotted.](elife-58243-fig8){#fig8}

We further analyzed the functional defects in eIF4A- and eIF4E binding mutants by measuring expression of three luciferase (*FLUC)* reporter mRNAs harboring a Ded1-hypodependent synthetic unstructured 5'UTR harboring no stem-loop (no SL), or either cap-distal or cap-proximal SLs shown previously to confer Ded1-hyperdepence both in vivo ([@bib27]) and in vitro ([@bib15]; [Figure 8B](#fig8){ref-type="fig"}). Relative to the *ded1-ts* parental mutant, introducing single- or double-cluster NTD mutations that impair binding to eIF4A or eIF4E, or control NTD mutations *14--20* and *40--47* with no effect on eIF4A/eIF4E binding, had little or no effect on expression of the reporter lacking a 5'UTR SL ([Figure 8C](#fig8){ref-type="fig"}, dark gray bars). The reporter with a cap-distal SL showed reduced expression relative to the no-SL construct in the *ded1-ts* parental strain ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, cols. 1--2), which was unaffected by the control NTD mutations; but was driven even lower by all of the mutations affecting eIF4A or eIF4E binding, with the greatest reductions seen for the two double substitutions *ded1-ts,21-27/51-57* and *ded1-ts,59-65/83-89* that eliminate, respectively, eIF4A or eIF4E binding to Ded1 ([Figure 8C](#fig8){ref-type="fig"}, light gray bars). Expression of the cap-proximal SL reporter was also reduced somewhat in the *ded1-ts* parental strain ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, col. 3 vs. 1), and was not further diminished by the control NTD mutations or the single cluster mutants defective for eIF4E binding (*59--65* and *83--89*), whereas the single cluster mutants defective for eIF4A binding (*21--27* and *51--57*) and both double-cluster mutants impairing eIF4A or eIF4E binding showed substantially reduced expression of this reporter, with the greatest reductions seen for the two double-cluster mutants ([Figure 8C](#fig8){ref-type="fig"}, white bars). Interestingly, overexpression of eIF4A conferred increased expression of the no SL and cap-distal reporters in the *ded1-ts/21--27* mutant, predicted to exhibit partially impaired binding of eIF4A to Ded1, but not in the *ded1-ts/21-27/51-57* or *ded1-ts/59-65/83-89* strains expected to be fully defective for eIF4A binding, or for eIF4E binding, respectively ([Figure 8---figure supplement 5](#fig8s5){ref-type="fig"}). This supports the notion that the defect in reporter expression conferred by *ded1-ts/21--27* involved impaired Ded1 association with eIF4A.

Finally, we verified that the decreased expression of the cap-proximal *FLUC* reporter in the Ded1 mutants results from impaired translation by examining the effects of the mutations on the polysome size distributions of the reporter mRNA, assayed by qRT-PCR of total mRNA isolated from each fraction of the density gradient used to resolve total ribosomal species, noting that a shift in mRNA abundance from larger to small polysomes, or from polysomes/monosomes to free mRNPs, indicates a reduction in the rate of translation initiation. In the parental *ded1-ts* mutant, the reporter mRNA is almost equally distributed among all gradient fractions ([Figure 8D (ii)](#fig8){ref-type="fig"}, gray points). In the eIF4E-binding mutant *ded1-ts,59-65/83-89,* the proportion of reporter mRNA in the heavy polysome fractions is reduced, and the proportion in the smallest polysomes and monosomes is increased ([Figure 8D (ii)](#fig8){ref-type="fig"}, orange points) relative to the mRNA distribution in the parental strain ([Figure 8D (ii)](#fig8){ref-type="fig"}, grey points). Moreover, in the eIF4A binding mutant *ded1-ts,21-27/51-57*, the proportion of reporter mRNA in heavy polysomes is reduced and the proportion in free mRNP is elevated ([Figure 8D (ii)](#fig8){ref-type="fig"}, green points) compared to that seen in the *ded1-ts* strain ([Figure 8D (ii)](#fig8){ref-type="fig"}, grey points). The more extensive shift from polysomes to free mRNP observed for the eIF4A-binding mutant compared to the shift from larger to smaller polysomes/monosomes conferred by the eIF4E-binding mutant ([Figure 8D (ii)](#fig8){ref-type="fig"}, green vs. orange) is consistent with the relatively greater reductions in cap-proximal SL reporter expression given by the set of three eIF4A-binding mutants versus the three eIF4E-binding mutants ([Figure 8C](#fig8){ref-type="fig"}, eIF4A(-) vs. eIF4E(-) mutants). This shift of the reporter mRNA from polysomes to free mRNP in the eIF4A-binding mutant or to smaller polysomes in the eIF4E-binding mutant is statistically significant ([Figure 8---figure supplement 4](#fig8s4){ref-type="fig"}). In contrast to the behavior of the reporter mRNA, the polysome distribution of native *ACT1* mRNA was not substantially altered by either of the Ded1 NTD mutations ([Figure 8D](#fig8){ref-type="fig"} (i)), suggesting that Ded1's interactions with eIF4A and eIF4E are relatively more important for the reporter mRNA harboring a stable SL structure compared to *ACT1* mRNA. *ACT1* mRNA was not found to be hyperdependent on Ded1 by ribosome profiling of a *ded1* mutant ([@bib27]). These results confirm that loss of eIF4A and eIF4E interactions by the Ded1 NTD lead to reduced translation initiation of a Ded1-hyperdependent reporter mRNA, as well as to decreased bulk translation initiation in vivo.

Assaying expression of the same *LUC* reporters, we found that the single amino acid mutations in the eIF4A binding region *Y21A* and *R27A* reduced expression of only the cap-distal SL (*Y21A*) or both SL reporters (*R27A*), and that the *Y65A* and *W88A* single-residue mutations in the eIF4E binding region reduced expression of both SL reporters, compared to the parental *ded1-ts* strain ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}), thus supporting the importance of these individual residues in Ded1 NTD interactions with eIF4A and eIF4E in vivo.

We also provided evidence that eliminating both eIF4A and eIF4E binding simultaneously essentially inactivates the Ded1 NTD in promoting bulk translation as well as translation of Ded1-hyperdependent reporter mRNAs. As shown in [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}, the *21-27/51-57/59-65/83-89* quadruple-cluster mutation and the *Δ2--90* deletion of the NTD introduced into otherwise WT *DED1* conferred nearly indistinguishable reductions in bulk polysome assembly (panel A) and expression of both cap-proximal SL and cap-distal SL *FLUC* reporters (panel B). In both assays, the defects were quantitatively smaller than shown above for the double-cluster mutations in [Figure 8A](#fig8){ref-type="fig"} and [5C](#fig5){ref-type="fig"}, which we attribute to the absence of the *ded1-ts* mutation in the parental and mutant alleles being compared in the current assays.

Finally, we obtained evidence that the effect of NTD mutations in exacerbating the effect of deleting the Ded1 CTD shown above in cell growth assays ([Figure 4](#fig4){ref-type="fig"}) could also be observed in the functional assays for polysome assembly and reporter mRNA expression. As shown in [Figure 8---figure supplement 3A](#fig8s3){ref-type="fig"}, the *ded1-ΔC* mutation analyzed above has little or no effect on polysome assembly on its own (cf. panels (i)-(ii)). However, *ΔC* clearly exacerbates the effects of both the *21-27/51-57* and *59-65/83-89* double-cluster mutations in the Ded1 NTD in reducing P/M ratios, with a relatively greater effect for the *21-27/51-57* mutation that eliminates eIF4A binding (cf. (iii)-(iv) and (v)-(vi)). Similarly, *ded1-ΔC* alone has only small effects on expression of the SL-containing *FLUC* reporters, but *ΔC* exacerbates the reductions in reporter expression conferred by *21-27/51-57* ([Figure 8---figure supplement 3B](#fig8s3){ref-type="fig"}, set four vs. sets 2 and 3) and by the *59-65/83-89* mutation ([Figure 8---figure supplement 3B](#fig8s3){ref-type="fig"}, set six vs. sets 2 and 5). These findings support our conclusion that eliminating eIF4G association with the Ded1 CTD imposes a relatively greater requirement for the Ded1 NTD interactions with eIF4A and eIF4E, either in forming or stabilizing the eIF4F·Ded1 complex or in stimulating Ded1 unwinding activity.

Disruption of Ded1-eIF4A or eIF4E interactions impairs 48S PIC assembly on a SL-containing mRNA in the purified system {#s2-7}
----------------------------------------------------------------------------------------------------------------------

The yeast reconstituted system provides a unique mechanistic view of translation initiation ([@bib1]; [@bib2]; [@bib15]; [@bib19]), which allowed us previously to reconstitute the function of Ded1 in stimulating the rate of 48S PIC assembly on native mRNAs, and to demonstrate substantially greater rate-enhancement for mRNAs that harbor structured 5'UTRs that confer hyperdependence on Ded1 for efficient translation in vivo, compared to mRNAs with less structured 5'UTRs that are Ded1-hypodependent in cells. Moreover, we showed that deleting the N-terminal 116 residues of Ded1 (ΔNTD~1-116~) reduced the maximum rate of PIC assembly achieved at saturating levels of Ded1 (k~max~) and increased the concentration of Ded1 required for the half-maximal rate (K~1/2~) for several mRNAs containing stable SL structures in the 5'UTRs ([@bib15]). As eliminating the entire N-terminal region did not distinguish between impairing binding to eIF4A, eIF4E, or eliminating some other stimulatory function of this region of Ded1, we sought to determine whether selectively impairing Ded1 interaction with eIF4A or eIF4E would impair Ded1 acceleration of 48S assembly on a SL-containing mRNA. Accordingly, we purified full-length (FL) WT Ded1, Ded1-ΔNTD~1-116~ and the two Ded1 variants harboring the double clustered substitutions that disrupt binding to eIF4A 21-27/51-57, or the single cluster substitution 59--65 that reduces binding to eIF4E, and compared them for acceleration of 48S PIC assembly on an mRNA (dubbed *CP-8.1*) containing the same cap-proximal SL present in the *FLUC* reporter mRNA analyzed above appended to the coding sequences and 3'UTR of of the Ded1-hypodependent native *RPL41A* mRNA. The three purified mutant proteins had ATPase activities similar to that of WT Ded1 (data not shown).

In agreement with previous results ([@bib15]), FL Ded1 substantially increased the k~max~ of 48S PIC formation on *CP-8.1* mRNA by \~5 fold compared to the absence of Ded1, and deleting the NTD diminished the rate enhancement conferred by addition of Ded1 compared to no Ded1 in the reaction by ≈60% ([Figure 9A](#fig9){ref-type="fig"}, cols. 1--3; see [Figure 9---figure supplement 1C](#fig9s1){ref-type="fig"} for data summary). Interestingly, disrupting eIF4A binding to the NTD with the 21-27/51-57 double substitutions was comparable to the ΔNTD~1-116~ in reducing k~max~, whereas the 59--65 substitution that affects eIF4E binding had no effect on the k~max~ ([Figure 9A](#fig9){ref-type="fig"}, cols. 3--5). The ΔNTD~1-116~ truncation also greatly increased the K~1/2~ for Ded1 on this mRNA ([Figure 9B](#fig9){ref-type="fig"}, cols. 1--2), as observed previously ([@bib15]); and both the 21-27/51-57 and 59--65 substitutions also increased the K~1/2~ for Ded1 to an extent ≈40% of that given by the ΔNTD~1-116~ ([Figure 9B](#fig9){ref-type="fig"}, cols. 2--4). These findings suggest that binding of eIF4A, but not eIF4E, to the Ded1 NTD is required for maximum acceleration of 48S PIC assembly on *CP-8.1* mRNA, but that both eIF4A and eIF4E interactions decrease the amount of Ded1 required to achieve this stimulation, possibly by enhancing formation of the eIF4F·Ded1 complex ([@bib15]).

![Disruption of Ded1 NTD interactions with eIF4A or eIF4E alter the kinetics of 48S assembly in the reconstituted system for a synthetic mRNA with Cap-proximal SL.\
(**A--B**) Kinetics of 48S PIC assembly was analyzed in reactions containing reconstituted 43S PICs, a radiolabeled capped reporter mRNA containing a cap-proximal SL of predicted ΔG of −8.1kcal/mol located five nt from the 5'end (depicted schematically), and different concentrations of mutant or WT Ded1 protein. Formation of 48S PICs was detected using a native gel mobility shift assay and measured as a function of time, allowing determination of observed rates at each Ded1 concentration. The maximum rates (k~max~) (**A**) and Ded1 concentration at the half-maximal rate (K~1/2~) (**B**) were determined from three replicate sets of assays and the individual values (black points) and mean values (bar heights) are plotted for experiments containing no Ded1, WT full-length Ded1 (FL Ded1), Ded1 lacking N-terminal residues 2--116 (ded1ΔNTD), or FL Ded1 harboring the indicated NTD substitutions that impair binding to eIF4A (green bars) or eIF4E (orange bars). (**C**) Model to account for the greater requirements for the Ded1-NTD interactions with eIF4A and eIF4E in stimulating translation of mRNAs with strong secondary structures versus relatively unstructured 5'UTRs. Ded1 interactions with each of the subunits of the eIF4F complex lowers the concentration of Ded1 required for its recruitment to the capped 5' ends of all mRNAs, where it can unwind structures that impede PIC attachment or scanning to the start codon. Structured mRNAs (*right*) require a more stable association between Ded1 and eIF4F for maximum Ded1 recruitment and, hence, are relatively more dependent on having both eIF4A and eIF4E contacts with the Ded1 NTD intact. Unwinding stable SL structures for the latter additionally requires the enhancement of Ded1 unwinding activity conferred by its interaction with eIF4A (red arrows on the *right*) to achieve maximum acceleration of PIC attachment or scanning. (**D**) Schematic summary of the relative importance of interactions of the Ded1 NTD with eIF4A and eIF4E and the Ded1 CTD with eIF4G, in stimulating Ded1 recruitment to mRNA and its RNA helicase activity. (i) In WT cells, Ded1's multiple interactions with the subunits of eIF4F enhance recruitment of Ded1 in complex with eIF4F to the m^7^G cap to form a stable activated mRNP, which can subsequently recruit the 43S PIC and efficiently scan the 5'UTR to locate the AUG codon (not depicted). Eliminating the Ded1 CTD and its direct contact to eIF4G (ii, red Δ), confers a modest reduction in Ded1 function, whereas greater reductions are conferred by substitution mutations in the Ded1 NTD (red asterisks) that impair Ded1 interaction with eIF4E (iii) or eIF4A (iv). Even greater decreases in Ded1 function are seen on combining each of the Ded1 NTD substitutions with deletion of the Ded1 CTD (v--vi).\
Figure 9---source data 1.CP-8.1 mRNA recruitment source data.](elife-58243-fig9){#fig9}

We showed previously that Ded1 also increases the rate of 48S PIC assembly on Ded1-hypodependent *RPL41A* mRNA, but to a lesser degree and at a much lower Ded1 concentration compared to Ded1-hyperdependent mRNAs such as *CP-8.1* (analyzed above). As observed previously ([@bib15]), FL Ded1 increased the k~max~ for *RPL41A* mRNA by \~3 fold, and eliminating the Ded1 NTD by ΔNTD~1-116~ did not impair this stimulation ([Figure 9---figure supplement 1A](#fig9s1){ref-type="fig"}, cols. 2--3); however, ΔNTD~1-116~ increased the K~1/2~ for Ded1 on *RPL41A* mRNA by nearly 70-fold ([Figure 9---figure supplement 1B](#fig9s1){ref-type="fig"}, cols. 2--3). As expected, neither the 21-27/51-57 double substitution nor the 59--65 substitution altered the increase in k~max~ for *RPL41A* mRNA conferred by FL Ded1 ([Figure 9---figure supplement 1A](#fig9s1){ref-type="fig"}, cols. 4--5 vs. 2). While both substitutions increased the K~1/2~ for Ded1 compared to FL-Ded1 (\~7 fold for 21-27/51-57 and \~4 fold for the 59--65 substitution), these increases were much smaller than the \~70 fold increase produced by ΔNTD~1-116~ ([Figure 9---figure supplement 1B](#fig9s1){ref-type="fig"}, cols. 3--4 vs. 2 cf. col.1;and [Figure 9---figure supplement 1D](#fig9s1){ref-type="fig"}, cols. 4--5 vs. 2 cf. col. 1). These last results suggest that strong interaction of either eIF4A or eIF4E with the Ded1-NTD is sufficient to greatly reduce the amount of Ded1 required for maximum acceleration of 48S PIC assembly on *RPL41A *mRNA. This contrasts with our findings on *CP-8.1* mRNA, where eliminating either of the interactions of the Ded1-NTD with eIF4A and eIF4E conferred an increase in the Ded1 K~1/2~ only slightly smaller than that given by deleting the entire NTD. Thus, it appears that both interactions are needed simultaneously to enhance the function of the eIF4F-Ded1 complex on the more structured *CP-8.1* mRNA, whereas each interaction can contribute independently and additively on the less structured *RPL41A* mRNA.

Discussion {#s3}
==========

In previous studies, segments of the N-terminus of Ded1 have been shown to be required for rapid cell growth at a reduced temperature ([@bib16]; [@bib12]; [@bib13]), robust translation of a reporter mRNA in cell extracts ([@bib16]), the stimulatory effect of eIF4A on Ded1 unwinding activity in vitro ([@bib13]), and wild-type acceleration of 48S PIC assembly on particular mRNAs in the yeast reconstituted system ([@bib15]). Ded1 physically interacts with eIF4E ([@bib29]), but the eIF4E binding site within Ded1 was unknown. Importantly, it was also unclear whether Ded1's individual interactions with eIF4A or eIF4E are critical for Ded1 function in vivo in stimulating bulk protein synthesis and the translation of particular mRNAs with heightened Ded1-dependence conferred by 5'UTR structures. Finally, whereas interaction of the Ded1 CTD with eIF4G appears to enhance Ded1 unwinding function in vitro ([@bib24]; [@bib13]), the ability of Ded1 to stimulate reporter translation in cell extracts ([@bib16]) and 48S PIC assembly on particular mRNAs in a purified system ([@bib15]), it has been unclear whether this Ded1·eIF4G interaction is critical for Ded1 stimulation of translation in vivo. Our results fill in these important gaps in knowledge of how Ded1 stimulates translation initiation in living cells.

We have identified discrete, non-overlapping clusters of amino acids in the Ded1 NTD, as well as individual residues within these clusters, that appear to provide binding determinants for eIF4A or eIF4E, as their substitutions with alanine selectively reduce Ded1 binding to either GST-eIF4A or GST-eIF4E fusions in vitro. Binding determinants for eIF4A map between residues 21--27, including the highly conserved residue Arg-27, and also between residues 51--57, and appear to make independent, additive contributions to eIF4A binding. Binding determinants for eIF4E are located between residues 59--65, including Tyr-65, and between residues 83--89, including the highly conserved Trp-88, and appear to make concerted contributions to eIF4E binding. It is possible that additional binding determinants for eIF4E or eIF4A are located within the adjacent NTE extension of the helicase domain, which was not analyzed here, or within the Ded1 CTD ([Figure 1D](#fig1){ref-type="fig"}). Nevertheless, because the clustered NTD substitutions we identified selectively impair Ded1 binding to eIF4A or eIF4E in vivo at native levels of Ded1 expression, they provided us with the genetic tools needed to investigate whether Ded1's individual interactions with eIF4A or eIF4E are crucial for robust Ded1 function in vivo.

Armed with these Ded1 variants, we obtained evidence that disrupting Ded1-NTD interactions with either eIF4A or eIF4E reduces cell growth and bulk translation initiation, and preferentially impairs translation of reporters harboring 5'UTR SL structures in vivo. The Ded1 substitutions that impair interaction with eIF4A examined in combination with the *ded1-ts* mutation conferred a greater reduction in cell growth and an equal or somewhat greater impairment of the SL-containing reporters, but not a greater reduction in bulk polysomes, compared to the substitutions disrupting eIF4E binding to the Ded1 NTD. However, when introduced into otherwise WT Ded1, or the Ded1-ΔC variant, the substitutions perturbing eIF4A binding consistently impaired growth and both bulk and reporter translation more so than those impacting eIF4E binding. Thus, on balance, eIF4A interaction appears to be relatively more important than eIF4E interaction with the Ded1 NTD for strong translation initiation in vivo.

It was important to provide additional evidence that the Ded1 NTD substitutions impair translation initiation in vivo because they selectively impair Ded1 interactions with eIF4A or eIF4E rather than participating in some other aspect of Ded1 function. This was achieved for the substitutions that impair eIF4A binding by showing that overexpressing eIF4A mitigates the growth defects of NTD mutants *21--27* or *51--57*, which only partially impair eIF4A binding in vitro, but not of the double mutant *21-27*/*51-57* that appears to be incapable of binding eIF4A and, hence, should be refractory to a restoration of Ded1-eIF4A association by mass action. Nor did overexpressing eIF4A suppress the growth defects conferred by the *59-65/83-89* mutations that impair Ded1 binding to eIF4E. We used a different genetic approach to confirm that the latter NTD substitutions impair translation in vivo by diminishing Ded1-eIF4E association, by showing that overexpressing the 21-27/51-57 Ded1 variant, impaired for eIF4A association, behaves like overexpressed WT Ded1 and mitigates the phenotype of the eIF4E mutant *cdc33-1,* whereas overexpressing the 59-65/83-89 Ded1 variant selectively defective for eIF4E binding cannot rescue *cdc33-1* cells. While we cannot completely eliminate the possibility that the NTD mutations impair cell growth and translation in vivo by affecting some other aspect of Ded1 function with indirect consequences, these genetic suppression results provide confidence that Ded1-NTD interactions with eIF4A and eIF4E are physiologically important. It is noteworthy that the quadruple-cluster substitution mutation *21-27*/*51-57/59-65/83-89* that eliminates binding to both eIF4A and eIF4E confers a defect in cell growth greater than that seen for the two double-cluster substitutions that impair binding to only eIF4A or eIF4E, which is equivalent to that given by deleting the entire NTD (*Δ2--90*). These findings strongly suggest that eIF4A/eIF4E binding represents the crucial in vivo function of the Ded1 NTD.

The importance of the Ded1 CTD and its ability to interact with eIF4G in promoting translation initiation in vivo has been unclear, as its removal did not reduce growth in nutrient-replete cells; and while a deletion spanning the junction between the helicase core domain and the relatively conserved CTE was found to exacerbate the growth defects of two NTD mutations, a similar finding was not reported for a mutation affecting the more distal CTD domain ([@bib16]). Here, we found that truncating the Ded1 CTD impairs cell growth, bulk polysome assembly, and translation of reporter mRNA in vivo only in Ded1 variants additionally impaired for their association with eIF4A or eIF4E via the Ded1 NTD. In view of recent findings that the last 14 residues of the CTD are crucial for Ded1 binding to eIF4G in vitro ([@bib5]), our genetic findings imply that the interactions of Ded1 with each of the three subunits of eIF4F make independent, additive contributions to formation of the eIF4F·Ded1 complex and attendant stimulation of Ded1 helicase functions in promoting translation initiation. Interestingly, truncating the CTD to eliminate its ability to bind eIF4G confers resistance to cell growth inhibition by rapamycin, implicating the Ded1-CTD/eIF4G interaction in TORC1-mediated down-regulation of translation during nutrient starvation ([@bib5]) beyond its stimulatory function in nutrient-replete cells.

Using the reconstituted yeast system, we obtained evidence that individually disrupting Ded1-NTD interactions with either eIF4A or eIF4E impaired the ability of Ded1 to accelerate PIC assembly on a reporter mRNA harboring a cap-proximal SL. As we observed for a cap-proximal *FLUC* reporter in cells, Ded1 interaction with eIF4A was important for 48S PIC assembly on a cap-proximal SL reporter mRNA in vitro, as the Ded1 variant selectively impaired for eIF4A binding (21-27/51-57) reduced the maximum rate of PIC assembly (k~max~) and also increased the amount of that variant required to achieve half-maximal rate stimulation (K~1/2~) compared to WT Ded1. The Ded1 variant impaired for binding eIF4E (59-65) increased the Ded1 K~1/2~ by a comparable amount, but did not reduce the k~max~ for the cap-proximal SL reporter. While this might suggest a lesser requirement for Ded1 interaction with eIF4E versus eIF4A for rapid PIC assembly on this structured mRNA, the single-cluster variant 59--65 analyzed in vitro is not impaired for translation of the cap-proximal *FLUC* reporter in vivo, and we were unable to purify and analyze the double-cluster mutant 59-65/83-89 lacking both eIF4E binding determinants, which is compromised for translation of the cap-proximal promoter in vivo.

Interestingly, for the Ded1-hypodependent mRNA *RPL41A,* containing a 5' UTR of only 22nt lacking recognizable secondary structure, the Ded1 NTD~1-116~, and hence interaction with both eIF4A and eIF4E, is dispensable for the modest \~2.5 fold increase in k~max~ afforded by Ded1. Importantly, however, the ΔNTD~1-116~ variant (incapable of eIF4A/eIF4E interactions) requires an \~70 fold higher concentration compared to WT Ded1 to achieve the same half-maximal acceleration (K~1/2~) on this mRNA. The 21-27/51-57 and 59--65 variants accelerate PIC assembly on *RPL41A* mRNA at \~10--20 times lower concentrations compared to ΔNTD~1-116~, indicating that interaction with either eIF4E or eIF4A by these substitution mutants is sufficient to increase the efficiency of Ded1 function on this mRNA compared to the absence of both interactions. For *CP-8.1* mRNA, by contrast, interaction with either eIF4E or eIF4A by the two aforementioned Ded1 variants confers only a small benefit, decreasing the K~1/2~ by \~2 fold, whereas having both interactions intact in WT Ded1 lowers the K~1/2~ by 7.6-fold, compared to ΔN~1-116~. Thus, while Ded1 interactions with eIF4A and eIF4E are important for Ded1 acceleration of PIC assembly on both mRNAs, the unstructured *RPL41A* mRNA appears to have a relatively smaller requirement for a full set of contacts between Ded1 and eIF4A/eIF4E in order for Ded1 to function at low concentrations. Moreover, *CP-8.1* additionally requires Ded1 contacts with eIF4A (impaired by substitutions 21-27/51-57) to overcome the SL structure and achieve maximum acceleration, even at high Ded1 concentrations.

One way to account for these differences between the *RPL41A* and *CP-8.1* mRNAs, depicted in the model shown in [Figure 9C](#fig9){ref-type="fig"}, would be to propose that the Ded1 interactions with the subunits of the eIF4F complex lowers the concentration of Ded1 required for its recruitment to the capped mRNA 5' end where it can unwind structures that impede PIC attachment or scanning to the start codon. This enhancement would apply to both unstructured and structured mRNAs, but structured mRNAs might require a more stable association between Ded1 and eIF4F for maximum Ded1 recruitment and, hence, be relatively more dependent on having both eIF4A and eIF4E contacts with the Ded1 NTD intact. Unwinding stable SL structures might additionally require the enhancement of Ded1 unwinding activity conferred by its interaction with eIF4A ([@bib13]) to achieve maximum acceleration of PIC attachment or scanning ([Figure 9C](#fig9){ref-type="fig"}).

Together, our findings indicate that the Ded1 NTD interacts directly with eIF4E and eIF4A via adjacent, non-overlapping segments of the NTD, and that these interactions, in concert with the Ded1-CTD interaction with eIF4G, make independent, additive contributions to Ded1 function in stimulating translation initiation in vivo. As summarized schematically in [Figure 9D](#fig9){ref-type="fig"}, in all of our in vivo assays of cell growth and bulk or reporter mRNA translation, eliminating Ded1 interaction with eIF4G by deleting the Ded1 CTD had a less severe impact than did impairing eIF4A or eIF4E binding to the Ded1 NTD, and the eIF4A interaction with Ded1 appeared to be the most important overall. Envisioning all of these interactions occurring simultaneously on an mRNA suggests that they should serve to tether Ded1 tightly to the activated eIF4F·mRNA complex and focus its helicase activity on the 5'UTR to unwind structures that impede PIC attachment or subsequent scanning ([Figure 9C](#fig9){ref-type="fig"}). Consistent with previous in vitro findings that interaction with eIF4A increases Ded1 unwinding activity ([@bib13]), our results here in the reconstituted system suggest that the Ded1-NTD interaction with eIF4A is particularly important for enhancing Ded1 unwinding of the SL structure in CP-8.1 mRNA. It remains to be determined whether the Ded1 interaction with eIF4E serves primarily to stabilize formation of the eIF4F·Ded1 complex and localize it to mRNA 5' ends, or whether, it too stimulates Ded1 unwinding activity. In summary, we envision that Ded1-NTD interactions with both eIF4A and eIF4E, and Ded1-CTD binding to eIF4G, all help to assemble and stabilize the eIF4F-Ded1 complex at the 5' ends of mRNAs, which enhances initiation of nearly all mRNAs, whereas the Ded1-NTD/eIF4A interaction is additionally important to stimulate Ded1 unwinding of strong secondary structures in mRNA 5'UTRs ([Figure 9C](#fig9){ref-type="fig"}). Given the much greater abundance of eIF4A compared to eIF4E and eIF4G ([@bib34]), the stimulation of Ded1 unwinding by eIF4A might also involve eIF4A molecules not tethered to eIF4F at the cap structure.

Materials and methods {#s4}
=====================

Plasmids and yeast strains {#s4-1}
--------------------------

All plasmids employed in this study are listed in [Table 1](#table1){ref-type="table"}. To create plasmids for bacterial expression of GST fusions to eIF4A1 and eIF4E, *TIF1* and *CDC33* coding sequences were amplified by PCR from the genomic DNA of WT yeast strain BY4741 (using primers listed in [Table 2](#table2){ref-type="table"}) and inserted between the BamHI and XhoI sites of pGEX4T1. pET-C-Ded1 cut with NdeI and XhoI was used to construct pSG49-pSG51 by inserting fragments encoding Ded1 residues 93--604 (pSG49), residues 1--561 (pSG50), or residues 93--561 (pSG51), PCR-amplified from pET-C-Ded1. Plasmids pSG52-pSG75 were derived from pET-C-Ded1 using the Agilent QuikChange Lightning Mutagenesis kit, according to the vendor's instructions, as were pSG76-pSG81 by mutagenesis of pET-N-Ded1. pSG1was constructed by inserting a fragment containing the *DED1* promoter (beginning 331 nt upstream of the AUG), entire coding sequence, coding sequence for the myc~13~ epitope, and the *ADH1* terminator, PCR-amplified from the genomic DNA of yeast strain H3666, between into the SphI and SacI sites of *LEU2/CEN4/ARS1* vector YCplac111. pSG2, containing *ded1-ts-myc* was derived from pSG1 by mutagenesis with Agilent QuikChange Lightning Mutagenesis kit to introduce the T408I/W253R substitutions. pSG27-pSG43 were derived from pSG1; and pSG3-pSG26 were derived from pSG2, by QuikChange mutagenesis. pSG44-pSG46 were similarly derived from p4504/YEplac195-DED1.

###### Plasmids and yeast alleles used in this study.

  Plasmid                Description                                                                 Source
  ---------------------- --------------------------------------------------------------------------- ------------------------
  YCplac111              empty vector                                                                [@bib14]
  pSG1                   *DED1-myc* in YCplac111                                                     This study
  pSG2                   *ded1-ts-myc* in YCplac111                                                  This study
  pSG3                   *ded1-ts/4--10-myc* in YCplac111                                            This study
  pSG4                   *ded1-ts/14--20-myc* in YCplac111                                           This study
  pSG5                   *ded1-ts/21--27-myc* in YCplac111                                           This study
  pSG6                   *ded1-ts/29--35-myc* in YCplac111                                           This study
  pSG7                   *ded1-ts/Δ40--47-myc* in YCplac111                                          This study
  pSG8                   *ded1-ts/51--57-myc* in YCplac111                                           This study
  pSG9                   *ded1-ts/59--65-myc* in YCplac111                                           This study
  pSG10                  *ded1-ts/68--74-myc* in YCplac111                                           This study
  pSG11                  *ded1-ts/83--89-myc* in YCplac111                                           This study
  pSG12                  *ded1-ts/90--95-myc* in YCplac111                                           This study
  pSG13                  *ded1-ts/21-27/29-35-myc* in YCplac111                                      This study
  pSG14                  *ded1-ts/21-27/51-57-myc* in YCplac111                                      This study
  pSG15                  *ded1-ts/59-65/83-89-myc* in YCplac111                                      This study
  pSG16                  *ded1-ts/21-27/51-57/59-65/83-89-myc* in YCplac111                          This study
  pSG17                  *ded1-ts/Δ2--90-myc* in YCplac111                                           This study
  pSG18                  *ded1-ts,Δ562--604-myc* in YCplac111                                        This study
  pSG19                  *ded1-ts/21-27/51-57/59-65/83-89-/Δ562--604-myc* in YCplac111               This study
  pSG20                  *ded1-ts,Δ2--90,Δ562--604-myc* in YCplac111                                 This study
  pSG21                  *ded1-ts/Y21A-myc* in YCplac111                                             This study
  pSG22                  *ded1-ts/R27A-myc* in YCplac111                                             This study
  pSG23                  *ded1-ts/G28A-myc* in YCplac111                                             This study
  pSG24                  *ded1-ts/F56A/F57A-myc* in YCplac111                                        This study
  pSG25                  *ded1-ts/Y65A-myc* in YCplac111                                             This study
  pSG26                  *ded1-ts/W88A-myc* in YCplac111                                             This study
  pSG27                  *ded1-21-27-myc* in YCplac111                                               This study
  pSG28                  *ded1-51-57-myc* in YCplac111                                               This study
  pSG29                  *ded1-59-65-myc* in YCplac111                                               This study
  pSG30                  *ded1-83-89-myc* in YCplac111                                               This study
  pSG31                  *ded1-21-27/51-57-myc* in YCplac111                                         This study
  pSG32                  *ded1-59-65/83-89-myc* in YCplac111                                         This study
  pSG33                  *ded1-21-27/51-57/59-65/83-89-myc* in YCplac111                             This study
  pSG34                  *ded1Δ2--90-myc* in YCplac111                                               This study
  pSG35                  *ded1Δ562--604-myc* in YCplac111                                            This study
  pSG36                  *ded1-21-27/Δ562--604-myc* in YCplac111                                     This study
  pSG37                  *ded1-51-57/Δ562--604-myc* in YCplac111                                     This study
  pSG38                  *ded1-59-65/Δ562--604-myc* in YCplac111                                     This study
  pSG39                  *ded1-83-89/Δ562--604-myc* in YCplac111                                     This study
  pSG40                  *ded1-21-27/51-57/Δ562--604-myc* in YCplac111                               This study
  pSG41                  *ded1-59-65/83-89/Δ562--604-myc* in YCplac111                               This study
  pSG42                  *ded1-21-27/51-57/59-65/83-89/Δ562--604-myc* in YCplac111                   This study
  pSG43                  *ded1Δ2--90,Δ562--604-myc* in YCplac111                                     This study
  p1992/YEplac195        empty vector                                                                [@bib14]
  p3333/pBAS3432         *TIF1* in YEplac195                                                         [@bib21]
  p3351                  *CDC33* in YEplac195                                                        [@bib10]
  p4504/YEplac195-DED1   *DED1* in YEplac195                                                         [@bib10]
  pSG44                  *ded1-21-27/51-57* in YEplac195                                             This study
  pSG45                  *ded1-59-65/83-89* in YEplac195                                             This study
  pSG46                  *ded1Δ2--90* in YEplac195                                                   This study
  p6053/pFJZ342          *RPL41A* 5\'UTR with 23 CAA repeats inserted (91nt long) in YCplac33        [@bib27]
  p6058/pFJZ669          *RPL41A* 5\'UTR with cap-proximal SL with ∆G of −8.1 kcal/mol in YCplac33   [@bib27]
  p6062/pFJZ623          *RPL41A* 5\'UTR with cap-distal SL with ∆G of −3.7 kcal/mol in YCplac33     [@bib27]
  p2917/pGEX-4T1         empty vector                                                                GE Healthcare 28954549
  pGEX-4G1               *TIF4631* in pGEX-4T1                                                       [@bib19]
  pSG47                  *TIF1* in pGEX-4T1                                                          This study
  pSG48                  *CDC33* in pGEX-4T1                                                         This study
  pET22b                 empty vector                                                                EMD Millipore 69744--3
  p5946/pET-C-Ded1       *DED1* in pET22b                                                            [@bib16]
  pSG49                  *ded1(93-604)-His* in pET22b                                                This study
  pSG50                  *ded1(1-561)-His* in pET22b                                                 This study
  pSG51                  *ded1(93-561)-His* in pET22b                                                This study
  pSG52                  *ded1-4-10-His* in pET22b                                                   This study
  pSG53                  *ded1-14-20-His* in pET22b                                                  This study
  pSG54                  *ded1-21-27-His* in pET22b                                                  This study
  pSG55                  *ded1-29-35-His* in pET22b                                                  This study
  pSG56                  *ded1-Δ40--47-His* in pET22b                                                This study
  pSG57                  *ded1-51-57-His* in pET22b                                                  This study
  pSG58                  *ded1-59-65-His* in pET22b                                                  This study
  pSG59                  *ded1-68-74-His* in pET22b                                                  This study
  pSG60                  *ded1-83-89-His* in pET22b                                                  This study
  pSG61                  *ded1-90-95-His* in pET22b                                                  This study
  pSG62                  *ded1-21-27/29-35-His* in pET22b                                            This study
  pSG63                  *ded1-21-27/51-57-His* in pET22b                                            This study
  pSG64                  *ded1-21-27/68-74-His* in pET22b                                            This study
  pSG65                  *ded1-51-57/59-65-His* in pET22b                                            This study
  pSG66                  *ded1-59-65/83-89-His* in pET22b                                            This study
  pSG67                  *ded1-Y21A-His* in pET22b                                                   This study
  pSG68                  *ded1-R27A-His* in pET22b                                                   This study
  pSG69                  *ded1-G28A-His* in pET22b                                                   This study
  pSG70                  *ded1-R51A-His* in pET22b                                                   This study
  pSG71                  *ded1-F56A/F57A-His* in pET22b                                              This study
  pSG72                  *ded1-R62A-His* in pET22b                                                   This study
  pSG73                  *ded1-Y65A-His* in pET22b                                                   This study
  pSG74                  *ded1-R83A-His* in pET22b                                                   This study
  pSG75                  *ded1-W88A-His* in pET22b                                                   This study
  pET-N-Ded1             *His-DED1* in pET15b                                                        [@bib15]
  pET-SUMO-ded1ΔN        *His-ded1Δ2--117* in pET-SUMO                                               [@bib15]
  pSG76                  *His-ded1-21* in pET15b                                                     This study
  pSG77                  *His-ded1-51* in pET15b                                                     This study
  pSG78                  *His-ded1-59* in pET15b                                                     This study
  pSG79                  *His-ded1-83* in pET15b                                                     This study
  pSG80                  *His-ded1-21,51* in pET15b                                                  This study
  pSG81                  *His-ded1-59,83* in pET15b                                                  This study
  pGIBS-LYS              *lysA*                                                                      ATCC \#87482
  pGIBS-TRP              *trpCDEF*                                                                   ATCC \#87485
  pGIBS-PHE              *pheB*                                                                      ATCC \#87483

###### Primer sequences used in this study.

  Primer                  5'-Sequence-3'                                                                                                     Source
  ----------------------- ------------------------------------------------------------------------------------------------------------------ ------------
  SG1/Ded1-13xmyc-F       TTTTTTGCATGCCCAAAGGTGTTCTTATGTAGTGACACCGAT                                                                         This study
  SG2/Ded1-13xmyc-R       TTTTTTGAGCTCTTACCCTGTTATCCCTAGCGGATCTGCCGG                                                                         This study
  SG134/W253R-F           AATTTACTTATAGATCCAGGGTCAAGGCCTGCGTC                                                                                This study
  SG135/W253R-R           GACGCAGGCCTTGACCCTGGATCTATAAGTAAATT                                                                                This study
  SG136/T408I-F           CAATTGATCTGCCATTCTCTTAATTTCGACAAAGATCAAAGTCAAA                                                                     This study
  SG137/T408I-R           TTTGACTTTGATCTTTGTCGAAATTAAGAGAATGGCAGATCAATTG                                                                     This study
  SG3/Cdc33-F             TTTTTTGGATCCTCCGTTGAAGAAGTTAGCAAG                                                                                  This study
  SG4/Cdc33-R             TTTTTTCTCGAGTTACAAGGTGATTGATGGTTG                                                                                  This study
  SG132/Tif1-F            TTTTTTGGATCCATGTCTGAAGGTATTACTGA                                                                                   This study
  SG133/Tif1-R            TTTTTTCTCGAGTTAGTTCAACAAAGTAGCGA                                                                                   This study
  SG5/pETded1(93-561)-F   GGGGGTCATATGCATGTCCCAGCTCCAAGAAA                                                                                   This study
  SG6/pETded1(93-561)-R   TTTTTTCTCGAGGCCTCCGGCCTTACGGTAAT                                                                                   This study
  SG7/pETded1(93-604)-F   TTTTTTCATATGCATGTCCCAGCTCCAAGAAAC                                                                                  This study
  SG8/pETded1(93-604)-R   TTTTTTCTCGAGCCACCAAGAAGAGTTGTTTGA                                                                                  This study
  SG9/pETded1(1-561)-F    TGTGTGCATATGGCTGAACTGAGCGAACAAGTG                                                                                  This study
  SG10/pETded1(1-561)-R   TTTTTTCTCGAGGCCTCCGGCCTTACGGTAAT                                                                                   This study
  SG41/pET4-s             GTGAGGAGGAACATAACCATTCTCGTTGTTGTCGTTGATGCTTAAAGCTGCCGCTGCTGCGGCCGCTTCAGCCATATGTATATCTCCTTCTTAAAGTTAAACAAAATTATTT   This study
  SG42/pET4-as            AAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGGCTGAAGCGGCCGCAGCAGCGGCAGCTTTAAGCATCAACGACAACAACGAGAATGGTTATGTTCCTCCTCAC   This study
  SG43/y4-s               GGAGGAACATAACCATTCTCGTTGTTGTCGTTGATGCTTAAAGCTGCCGCTGCTGCGGCCGCTTCAGCCATAATATGAAATGCTTTTCTTGTTGTTCTTACGGA           This study
  SG44/y4-as              TCCGTAAGAACAACAAGAAAAGCATTTCATATTATGGCTGAAGCGGCCGCAGCAGCGGCAGCTTTAAGCATCAACGACAACAACGAGAATGGTTATGTTCCTCC           This study
  SG45/14 s               CTTGGTTTTCCTCTTAAGTGAGGAGGAACATAAGCAGCCGCGGCGGCGGCGGCGATGCTTAAATTTTGCACTTGTTCGCTCAGTTCAGCCA                        This study
  SG46/14-as              TGGCTGAACTGAGCGAACAAGTGCAAAATTTAAGCATCGCCGCCGCCGCCGCGGCTGCTTATGTTCCTCCTCACTTAAGAGGAAAACCAAG                        This study
  SG47/21 s               TTGCTACTGTTATTTCTGGCACTTCTTGGTTTTCCTGCTGCGGCAGCAGCAGCAGCACCATTCTCGTTGTTGTCGTTGATGCTTAAATTTTGCACTTG                 This study
  SG48/21-as              CAAGTGCAAAATTTAAGCATCAACGACAACAACGAGAATGGTGCTGCTGCTGCTGCCGCAGCAGGAAAACCAAGAAGTGCCAGAAATAACAGTAGCAA                 This study
  SG49/29 s               GTTGTAGCCGCCGTTGTTGTTATTGTAGTTGCTACTGTTAGCTGCTGCAGCTGCTGCTGCTCCTCTTAAGTGAGGAGGAACATAACCATTCTCGTTGTTG               This study
  SG50/29-as              CAACAACGAGAATGGTTATGTTCCTCCTCACTTAAGAGGAGCAGCAGCAGCTGCAGCAGCTAACAGTAGCAACTACAATAACAACAACGGCGGCTACAAC               This study
  SG51/51 s               ACCACCACGACGGTTGTTGCTAGCGGCGGCGGCAGCGGCAGCGCCACCGTTGTAGCCGCCGTTG                                                   This study
  SG52/51-as              CAACGGCGGCTACAACGGTGGCGCTGCCGCTGCCGCCGCCGCTAGCAACAACCGTCGTGGTGGT                                                   This study
  SG53/68 s               CGTTAGATCTGCTGCCACCGTTGGCTGCAGCGGCGGCAGCAGCGTTGCCGTAACCACCACGACGG                                                  This study
  SG54/68-as              CCGTCGTGGTGGTTACGGCAACGCTGCTGCCGCCGCTGCAGCCAACGGTGGCAGCAGATCTAACG                                                  This study
  SG55/83 s               TTGGAGCTGGGACATGTTTGCCATCGGCCGCTGCAGCAGCAGCAGCGCCGTTAGATCTGCTGCCACCGTTGT                                           This study
  SG56/83-as              ACAACGGTGGCAGCAGATCTAACGGCGCTGCTGCTGCTGCAGCGGCCGATGGCAAACATGTCCCAGCTCCAA                                           This study
  SG57/90 s               GATCTCGGCCTTTTCGTTTCTTGCAGCTGCGGCAGCTGCGGCAGCGATCCATCTACCACCAGAACGG                                                This study
  SG58/90-as              CCGTTCTGGTGGTAGATGGATCGCTGCCGCAGCTGCCGCAGCTGCAAGAAACGAAAAGGCCGAGATC                                                This study
  SG105/40del-s           AAATAACAGTAGCAACAACGGTGGCCGTGGCG                                                                                   This study
  SG106/40del-as          CGCCACGGCCACCGTTGTTGCTACTGTTATTT                                                                                   This study
  SG303/59 s              TTCCACCGAAGAAACCACCGTTGCCGGCAGCAGCAGCAGCGGCGGCGCTAAAGAAGCTGCCACCGCCACGGC                                           This study
  SG304/59-as             GCCGTGGCGGTGGCAGCTTCTTTAGCGCCGCCGCTGCTGCTGCTGCCGGCAACGGTGGTTTCTTCGGTGGAA                                           This study
  SG305/59on51-s          CACCGAAGAAACCACCGTTGCCGGCAGCAGCAGCAGCGGCGGCGCTAGCGGCGGCGGCAGCGGCAG                                                 This study
  SG306/59on51-as         CTGCCGCTGCCGCCGCCGCTAGCGCCGCCGCTGCTGCTGCTGCCGGCAACGGTGGTTTCTTCGGTG                                                 This study
  SG195/R27A-s            CTTCTTGGTTTTCCTGCTAAGTGAGGAGGAACATAACCATTCTCG                                                                      This study
  SG196/R27A-as           CGAGAATGGTTATGTTCCTCCTCACTTAGCAGGAAAACCAAGAAG                                                                      This study
  SG197/R51A-s            CTAAAGAAGCTGCCAGCGGCAGCGCCACCGTTGTAGCC                                                                             This study
  SG198/R51A-as           GGCTACAACGGTGGCGCTGCCGCTGGCAGCTTCTTTAG                                                                             This study
  SG199/R62A-s            GAAACCACCGTTGCCGTAAGCAGCAGCACGGTTGTTGCTAAAGAAG                                                                     This study
  SG200/R62A-as           CTTCTTTAGCAACAACCGTGCTGCTGCTTACGGCAACGGTGGTTTC                                                                     This study
  SG201/R83A-s            CCATCGATCCATCTACCAGCAGCAGCGCCGTTAGATCTGCTGCC                                                                       This study
  SG202/R83A-as           GGCAGCAGATCTAACGGCGCTGCTGCTGGTAGATGGATCGATGG                                                                       This study
  SG161/ydelC-s           CCGTAAGGCCGGAGGCGGTGAACAAAAGCTAAT                                                                                  This study
  SG162/ydelC-as          ATTAGCTTTTGTTCACCGCCTCCGGCCTTACGG                                                                                  This study
  SG265/y2-90del-s        CTGGGACATGTTTGCCATCCATAATATGAAATGCTTTTCTTGTTGTTC                                                                   This study
  SG266/y2-90del-as       GAACAACAAGAAAAGCATTTCATATTATGGATGGCAAACATGTCCCAG                                                                   This study
  SG233/Y21A-s            AAGTGAGGAGGAACAGCACCATTCTCGTTGTTGTCGTTGATGC                                                                        This study
  SG234/Y21A-as           GCATCAACGACAACAACGAGAATGGTGCTGTTCCTCCTCACTT                                                                        This study
  SG235/F56F57-s          CACGACGGTTGTTGCTAGCGGCGCTGCCACCGCCACGGC                                                                            This study
  SG236/F56F57-as         GCCGTGGCGGTGGCAGCGCCGCTAGCAACAACCGTCGTG                                                                            This study
  SG241/Y65A-s            CCACCGTTGCCGGCACCACCACGACGGTTGT                                                                                    This study
  SG242/Y65A-as           ACAACCGTCGTGGTGGTGCCGGCAACGGTGG                                                                                    This study
  SG243/W88A-s            CATGTTTGCCATCGATCGCTCTACCACCAGAACGGC                                                                               This study
  SG244/W88A-as           GCCGTTCTGGTGGTAGAGCGATCGATGGCAAACATG                                                                               This study
  SG249/G28A-s            TGGCACTTCTTGGTTTTGCTCTTAAGTGAGGAGGA                                                                                This study
  SG250/G28A-as           TCCTCCTCACTTAAGAGCAAAACCAAGAAGTGCCA                                                                                This study
  FZ158/Fluc-F            ATG GAA GAC GCC AAA AAC ATA AAG                                                                                    [@bib27]
  FZ159/Fluc-R            TTA CAA TTT GGA CTT TCC GCC CTT                                                                                    [@bib27]
  act1-F                  TGTGTAAAGCCGGTTTTGCC                                                                                               [@bib36]
  act1-R                  GATACCTCTCTTGGATTGAGCTTC                                                                                           [@bib36]

All yeast strains employed in this study are listed in [Table 3](#table3){ref-type="table"}. Novel strains SGY1-SGY43 harboring plasmid pSG1-pSG43, were constructed by plasmid shuffling using 5-fluoroorotic acid (5-FOA) ([@bib6]) from strain yRP2799, as follows. Transformants of yRP2799 containing the relevant *LEU2* pSGY plasmid were selected on SC-Leu-Ura, patched on medium of the same composition, and replica-plated to SC-Leu containing 1 mg/ml 5-FOA. After 48--72 hr at 30°C, Ura^-^ segregants were purified from patches able to grow on 5-FOA medium by streaking for single colonies on SC-Leu.

###### Yeast strains used in this study.

  Strain          Description                                                                                                                 Source
  --------------- --------------------------------------------------------------------------------------------------------------------------- -------------------
  F2041/yRP2799   *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pRP1560 (DED1 URA3)*                                                [@bib16]
  H3666           *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 DED1-myc~13~ HIS3*                                                                       [@bib11]
  F729/BY4741     *MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0*                                                                                         Research Genetics
  H4436^\*^       *MATa ade2 his3 leu2 trp1 ura3 pep4::HIS3 tif4631::leu2hisG tif4632::ura3 pEP88 (TIF4631-HA-Bam TRP1 CEN4)*                 [@bib22]
  F694            *MATa cdc33::LEU2 ade2 his3 leu2 trp1 ura3 p(CDC33, TRP1, ARS/CEN4)*                                                        [@bib3]
  F695            *MATa cdc33::LEU2 ade2 his3 leu2 trp1 ura3 p(cdc33-4-2, TRP1, ARS/CEN4)*                                                    [@bib3]
  F696            *MATa cdc33::LEU2 ade2 his3 leu2 trp1 ura3 p(cdc33-1, TRP1, ARS/CEN4)*                                                      [@bib3]
  SGY1            *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG1* (*DED1-myc LEU2*)                                             This study
  SGY2            *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG2* (*ded1-ts-myc LEU2*)                                          This study
  SGY3            *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG3* (*ded1-ts/4--10-myc LEU2*)                                    This study
  SGY4            *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG4* (*ded1-ts/14--20-myc LEU2*)                                   This study
  SGY5            *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG5* (*ded1-ts/21--27-myc LEU2*)                                   This study
  SGY6            *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG6* (*ded1-ts/29--35-myc LEU2*)                                   This study
  SGY7            *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG7* (*ded1-ts/Δ40--47-myc LEU2*)                                  This study
  SGY8            *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG8* (*ded1-ts/51--57-myc LEU2*)                                   This study
  SGY9            *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG9* (*ded1-ts/59--65-myc LEU2*)                                   This study
  SGY10           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG10* (*ded1-ts/68--74-myc LEU2*)                                  This study
  SGY11           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG11* (d*ed1-ts/83--89-myc LEU*2)                                  This study
  SGY12           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG12* (*ded1-ts/90--95-myc LEU2*)                                  This study
  SGY13           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG13* (*ded1-ts/21-27/29-35-myc LEU2*)                             This study
  SGY14           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG14* (*ded1-ts/21-27/51-57-myc LEU2*)                             This study
  SGY15           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG15* (*ded1-ts/59-65/83-89-myc LEU2*)                             This study
  SGY16           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG16* (*ded1-ts/21-27/51-57/59-65/83-89-myc LEU2*)                 This study
  SGY17           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG17* (*ded1-ts,Δ2--90-myc LEU2*)                                  This study
  SGY18           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG18* (*ded1-ts,Δ562--604-myc LEU2*)                               This study
  SGY19           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG19* (*ded1-ts/21-27/51-57/59-65/83-89-myc/Δ562--604-myc LEU2*)   This study
  SGY20           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG20* (*ded1-ts,Δ2--90,Δ562--604-myc LEU2*)                        This study
  SGY21           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG21* (*ded1-ts/Y21A-myc LEU2*)                                    This study
  SGY22           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG22* (*ded1-ts/R27A-myc LEU2*)                                    This study
  SGY23           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG23* (*ded1-ts/G28A-myc LEU2*                                     This study
  SGY24           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG24* (*ded1-ts/F56A/F57A-myc LEU2*)                               This study
  SGY25           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG25* (*ded1-ts/Y65A-myc LEU2*)                                    This study
  SGY26           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG26* (*ded1-ts/W88A-myc LEU2*)                                    This study
  SGY27           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG27* (*ded1-21-27-myc LEU2*)                                      This study
  SGY28           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG28* (*ded1-51-57-myc LEU2*)                                      This study
  SGY29           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG29* (*ded1-59-65-myc LEU2*)                                      This study
  SGY30           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG30* (*ded1-83-89-myc LEU2*)                                      This study
  SGY31           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG31* (*ded1-21-27,51--57-myc LEU2*)                               This study
  SGY32           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG32* (*ded1-59-65,83--89-myc LEU2*)                               This study
  SGY33           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG33* (*ded1-21-27/51-57/59-65/83-89-myc-myc LEU2*)                This study
  SGY34           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG34* (*ded1Δ2--90-myc LEU2*)                                      This study
  SGY35           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG35* (*ded1Δ562--604-myc LEU2*)                                   This study
  SGY36           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG36* (*ded1-21-27/Δ562--604-myc LEU2*)                            This study
  SGY37           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG37* (*ded1-51-57/Δ562--604-myc LEU2*)                            This study
  SGY38           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG38* (*ded1-59-65/Δ562--604-myc LEU2*)                            This study
  SGY39           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG39* (*ded1-83-89/Δ562--604-myc LEU2*)                            This study
  SGY40           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG40* (*ded1-21-27/51-57/Δ562--604-myc LEU2*)                      This study
  SGY41           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG41* (*ded1-59-65/83-89/Δ562--604-myc LEU2*)                      This study
  SGY42           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG42* (*ded1-21-27/51-57/59-65/83-89-myc/Δ562--604-myc LEU2*)      This study
  SGY43           *MATa his3Δ1 leu2Δ0 lys2Δ0 met15Δ0 ura3Δ0 ded1Δ::kanMX4 pSG43* (*ded1-Δ2--90,Δ562--604-myc LEU2*)                           This study

\*The plasmid in this strain contains *TIF4631-HA* under the control of the *TIF4632* promoter and transcription terminator, as described previously ([@bib32]) modified to insert a BamHI site at the start codon ([@bib22]).

Yeast growth dilution-spot assays {#s4-2}
---------------------------------

Yeast strains were cultured in SC-Leu to A~600~ of \~1.0, dilutions of 10^−1^, 10^−2^, 10^−3^, and 10^−4^ were prepared in sterile water, and 5 μL aliquots of undiluted and diluted yeast cells were spotted on SC-Leu medium and incubated at the temperatures indicated in the figure legends.

Purification of recombinant GST fusion proteins expressed in *E. coli* {#s4-3}
----------------------------------------------------------------------

Agilent BL21-CodonPlus (DE3)-RIPL competent *E. coli* were transformed with pGEX4T1 or its derivatives containing the *TIF4631*, *TIF1* or *CDC33* coding sequences. Transformants were grown in 500 ml LB+Amp+Cam medium at 37°C to A~600~ of \~0.5 and protein expression induced by adding IPTG to 1 mM and incubating at 18°C overnight with agitation. Harvested cells were washed with 50 ml phosphate-buffered saline (PBS) and lysed by sonication in the presence of 50 μg/mL lysozyme and 10% glycerol. Lysates were treated with 10% Triton X-100 at 4°C and cleared by centrifugation at 10,000xg. 500 μL of GE Healthcare Glutathione Sepharose 4B beads were added per 20 mL of lysate and incubated with rotation overnight at 4°C. The beads were washed twice with 5 ml PBS in 10% glycerol and treated with 5000 gel units of NEB Micrococcal Nuclease in the presence of 2 mM calcium chloride in 1 ml PBS. The reaction was stopped by addition of EDTA to 5 mM, followed by washing the beads with 1 ml of 500 mM sodium chloride in PBS/glycerol. The beads were washed two more times with 1 ml PBS in 10% glycerol and the washed beads were stored at −80°C. SDS-polyacrylamide gel electrophoresis (SDS-PAGE), followed by Coomassie Blue staining, was employed to estimate the amounts of GST-tagged proteins bound to the glutathione-agarose beads by comparison to known amounts of bovine serum albumin.

In vitro translation of Ded1 polypeptides {#s4-4}
-----------------------------------------

Promega TNT Quick Coupled Transcription/Translation System was employed for in vitro translation of Ded1 proteins for GST pull-down assays. Perkin Elmer EasyTag L-\[^35^S\]-Methionine was used for radioactive labeling following the vendor's instructions.

In vitro GST pull down assays {#s4-5}
-----------------------------

GST pull down reactions were conducted as follows. Aliqouts of 10 μL of GST or GST-tagged bait proteins bound to glutathione-agarose beads were combined with 8 μL of pull-down buffer (40 mM Tris, pH 8.0, 0.01% IGEPAL CA630, 2 mM DTT, 50 mM NaCl, 20% glycerol, and 5 mM MgCl~2~), 0.5 μL of 5 mg/ml bovine serum albumin, 0.5 μL of ThermoFisher Scientific RNase A/T1 mix and 1 μL of \[^35^S\]-labeled Ded1 protein. The reactions were incubated at 4°C with end-over-end rotation overnight. The beads were washed three times with 30 μL of pull-down buffer without glycerol and proteins eluted with 20 μL 15 mM Glutathione \[pH 8.0\]. The input proteins and eluates were resolved by SDS-PAGE and visualized by fluorography, as follows. Gels were fixed in 50% methanol and 15% acetic acid, stained with Coomassie Blue, treated with Amersham Amplify Fluorographic Reagent, dried under vacuum and exposed to X-ray film for 18--72 hr at −80°C. After developing, the films and gels were scanned, and band intensities analyzed by NIH ImageJ software. Pull down efficiency was calculated as intensity of pulled down band divided by the corresponding input band intensity and converted to percentages. For statistical analyses, three or four replicates were performed. Unpaired student's *t* test was employed to determine p-values. GraphPad software was used to graph the data as dot plots.

Coimmunoprecipitation and western blots using yeast WCEs {#s4-6}
--------------------------------------------------------

For coimmunoprecipitation analysis, transformants of H3446 containing the relevant plasmid-borne *DED1-myc* alleles or empty vector were cultured in 100 mL of SC-Leu-Trp to A~600~ of \~0.8, harvested by centrifugation, washed with coimmunoprecipitation (CoIP) buffer (100 mM Tris-HCl pH 7.5, 100 mM sodium chloride, 0.1% NP-40, 1 mM DTT, 1 mM PMSF, 1 × Complete Protease Inhibitor Mix tablets without EDTA \[Roche\]) and lysed by vortexing with glass beads. Lysates were cleared by centrifugation and total protein amount determined colorimetrically using BioRad Bradford Reagent. The WCEs extracts were diluted to 5 mg/mL in CoIP buffer and aliquots of 1 mg (200 μL) were immunoprecipitated with 5 μg Roche anti-myc antibody (clone 9E10). After 2 hr of rotation at 4°C, 50 μL ThermoFisher Scientific Dynabeads Protein G were added and rotation continued for 2 hr more. Using a magnetic rack, the beads were washed three times with 150 μL CoIP buffer. The beads were resuspended in 100 μL 2x Laemmli buffer and boiled for 5 min. SDS-PAGE and Western blot were employed to detect the immunoprecipitated proteins, using the following antibodies: mouse monoclonal anti-HA antibody (12C5; Roche Cat\# 11 666 606 001), mouse monoclonal anti-c-Myc antibody (9E10; Roche Cat\# 11 667 203 001), rabbit polyclonal anti-eIF4A/Tif1 (kindly provided by Patrick Linder), rabbit polyclonal anti-eIF4E/Cdc33 (kindly provided by J.E.G. McCarthy), and rabbit polyclonal anti-Ded1 antibody (kindly provided by Dr. Tien-Hsien Chang). The immune complexes were visualized by enhanced chemiluminescence.

For Western blot analysis of yeast WCEs, trichloroacetic acid (TCA) precipitation was employed to extract total protein ([@bib26]), extracts were resolved by. SDS-PAGE, and Western blots were probed using the antibodies listed above, as well as rabbit polyclonal anti-Hcr1 antibodies ([@bib33]).

Luciferase reporter assays {#s4-7}
--------------------------

Two-ml cultures of yeast transformants harboring the relevant reporter plasmids were harvested by centrifugation and the cell pellets were washed with 500 μL PBS and lysed by vortexing with glass beads in 200 μL PBS supplemented with 1 × Complete Protease Inhibitor Mix tablets without EDTA \[Roche\]. Lysates were cleared by centrifugation, diluted 1:100 in PBS supplemented with 1 × Complete Protease Inhibitor Mix tablets without EDTA and luciferase was assayed using Promega Luciferase Assay System and a luminometer. Total protein concentration was measured colorimetrically using Bradford Reagent (BioRad) and known amounts of bovine serum albumin as standards. Luciferase units were normalized by the total protein amounts.

Polysome fractionation and analysis of mRNAs {#s4-8}
--------------------------------------------

For analyzing polysomes profiles, 200 mL of cells were cultured in the appropriate medium at 30°C and shifted to 36°C for 3 hr or to 15°C for 1 hr, and harvested at A~600~ ≈ 1. Cells were treated with 50 μg/ml cycloheximide for 5 min prior to harvesting. WCEs were prepared by resuspending the cell pellet with an equal volume of breaking buffer (20 mM Tris-HCl, pH 7.5, 50 mM KCl, 10 mM MgCl~2~, 1 mM dithiothreitol \[DTT\], 5 mM NaF, 1 mM phenylmethylsulfonyl fluoride \[PMSF\], 1 × Complete Protease Inhibitor Mix tablets without EDTA \[Roche\], 1 U/μl SUPERase-In RNase inhibitor) and vortexing with glass beads, followed by two cycles of centrifugation for 10 min at 15,000 rpm at 4°C. 20 A~260~ units of cleared lysate were resolved on 10--50% (w/w) sucrose gradients by centrifugation at 39,000 rpm for 160 min at 4°C in a Beckman SW41Ti rotor. Gradients were fractionated with a Brandel Fractionation System with continuous monitoring at 254 nm with an ISCO UV detector. Fractions (0.7 mL) were precipitated overnight at −20°C by adding 1.5 volumes of RNA precipitation mix (95% ethanol, 5% sodium acetate pH 5.2), and centrifuged at 15,000 rpm for 30 min. 5 ng of 'spike-in RNA' was added to each fraction to control for differences in RNA recovery: a mixture of in vitro transcribed capped *Bacillus subtilis* mRNAs ([@bib4]): 80 pg/µL lysA (prepared from plasmid pGIBS-LYS; ATCC\#87482), 160 pg/µl trpCDEF (prepared from plasmid pGIBS-TRP; ATCC\#87485), and 320 pg/µl of pheB (prepared from plasmid pGIBS-PHE; ATCC \#87483). This mixture of in vitro transcribed mRNAs was a kind gift from Dr. Neelam Sen ([@bib28]). Pellets were washed in 1 mL cold 80% ethanol, dried in a speed vacuum, resuspended in 100 µL TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA) and treated with 10 Kunitz units of DNase I. Qiagen RNEasy Mini kit was used to extract RNA and resuspended in 25 μL RNase-free water.

For RT-qPCR analysis of mRNA abundance in each gradient fraction, reverse transcription was carried out using SuperScript III First-Strand cDNA Synthesis SuperMix (Invitrogen) and 2 μL RNA purified from each gradient fractions. qPCR was carried out using Brilliant III Ultra-Fast SYBR Green Master Mix (Agilent) in a Mx3000P System (Stratagene) and the oligonucleotide pairs listed in [Table 2](#table2){ref-type="table"}. Normalization and analyses were performed as described in [@bib7] and [@bib27].

mRNA recruitment assays in the yeast reconstituted system {#s4-9}
---------------------------------------------------------

### Preparation and purification of mRNAs, charged initiator tRNA and translation initiation factors {#s4-9-1}

Plasmids for in vitro run-off mRNA and initiator tRNA transcription are described in [@bib1]; [@bib19]; [@bib15]. *RPL41A* mRNA represents the full-length native transcript. CP-8.1 mRNA has an unstructured 5'UTR comprised of CAA repeats with a stem-loop inserted five nt from the cap appended to the body of *RPL41A*. The mRNAs were transcribed, purified and capped as described in [@bib15]. Initiator tRNA was transcribed, methionylated and purified as described previously ([@bib35]). mRNAs were capped (m^7^GpppG) in vitro using vaccinia virus D1/D12 capping enzyme with either α-^32^P radiolabeled GTP (Perkin Elmer) or unlabeled GTP (for pulse-chase) ([@bib19]). Eukaryotic initiation factors, 40S ribosomal subunits, and WT Ded1 and its mutant derivatives were expressed and purified as described previously ([@bib1]; [@bib19]; [@bib20]; [@bib15]).

The Ded1 proteins bearing N-terminal His~6~-tags (Genscript) were expressed from the appropriate pET22b vectors in *E. coli* strain BL21(DE3) RIL CodonPlus cells (Agilent) by culturing cells in LB medium at 37°C to A~600~ of \~0.5, cooled to 20°C, and induced by addition of IPTG to 0.5 mM for 16 hr. Cells were harvested and resuspended in 35 mL lysis buffer (10 mM HEPES-KOH, pH-7.4, 200 mM KCl, 0.1% IGEPAL CA-630, 10 mM imidazole, 10% glycerol, 10 mM 2-mercaptoethanol, and cOmplete protease inhibitor cocktail (Roche)) and lysed using a French Press. The cell lysate was treated with DNaseI (1 U/mL) for 20 min on ice and the KCl concentration was adjusted to 500 mM. His~6~-Ded1 proteins were affinity-purified using a nickel column (5 ml His-Trap column, GE Healthcare). Fractions containing the Ded1 proteins were collected, the glycerol concentration was adjusted to 30%, and the Ded1 was further purified by phosphocellulose chromatography (P11, Whatman). Purified Ded1 proteins were dialyzed against dialysis buffer (10 mM HEPES-KOH, pH 7.4, 200 mM KOAc, 50% Glycerol, 2 mM DTT) and stored at −80°C.

### mRNA recruitment kinetics {#s4-9-2}

mRNA recruitment kinetics were performed using a native gel shift assay as described previously ([@bib19]; [@bib35]). This assay determines the apparent rates (k~app~) and maximal rates (k~max~) of recruitment as well as the concentration of a factor required to achieve half-maximal rate of recruitment (K~1/2~). Briefly, PICs were assembled with 300 nM eIF2, 0.5 mM GDPNP·Mg^2+^, 200 nM Met-tRNA~i~^Met^, 1 µM eIF1, 1 µM eIF1A, 300 nM eIF5, 300 nM eIF4B, 300 nM eIF3, 75 nM eIF4E·eIF4G, 7 µM eIF4A (15 µM for *SFT2* mRNA) and 30 nM 40S subunits in 1X Recon buffer (30 mM HEPES-KOH, pH 7.4, 100 mM KOAc, 3 mM Mg(OAc)~2~, and 2 mM DTT). The concentration of Ded1 was varied in the reactions from 0 to 1000 nM for WT Ded1 and 0--6000 nM for the Ded1 variants. Complexes were assembled at 26°C for 10 min and reactions were initiated by addition of 15 nM ^32^P-m^7^G capped mRNA and 5 mM ATP·Mg^2+^. Reactions were quenched by addition of 600--750 non-radiolabeled m^7^G-mRNA at appropriate times ([@bib19]; [@bib35]) and 48S PICs were separated from the free mRNA on a 4% non-denaturing PAGE gel. The fraction of the mRNA recruited to the 48S PIC at each time-point was calculated using ImageQuant software (GE Healthcare). Data were fitted with a single exponential rate equation and hyperbolic equations (KaleidaGraph software (Synergy)) to determine the apparent rates (k~app~) and maximal rates (k~max~) of recruitment as well as the concentration of a factor required to achieve half-maximal rate of recruitment (K~1/2~). Bar-graph data representations were prepared using Prism 7 (GraphPad).

Multiple sequence alignments {#s4-10}
----------------------------

T-Coffee ([www.ebi.ac.uk/Tools/msa/tcoffee](http://www.ebi.ac.uk/Tools/msa/tcoffee)) was used to align Ded1 amino acid sequences from fungal and animal species. Saccharomyces Genome Database (<https://www.yeastgenome.org/>) was the source of Ded1 sequences from the genus Saccharomyces. Other sequences were retrieved from NCBI Protein (<https://www.ncbi.nlm.nih.gov/protein>) and UniProt (<https://www.uniprot.org/>). The results were reformatted with MView ([www.ebi.ac.uk/Tools/msa/mview](http://www.ebi.ac.uk/Tools/msa/mview)) and WebLogo ([weblogo.berkeley.edu](http://weblogo.berkeley.edu/)).

Funding Information
===================

This paper was supported by the following grant:

-   http://dx.doi.org/10.13039/100000002National Institutes of Health Intramural Research Program to Suna Gulay, Neha Gupta, Jon R Lorsch, Alan G Hinnebusch.

We thank Roy Parker, Angie Hilliker, Alan Sachs, Patrick Linder, and Michael Altmann for gifts of yeast strains or plasmids, Patrick Linder, JEG McCarthy, and Tien-Hsien Chang for gifts of antibodies, and Neelam Sen for spike-in RNAs. We thank Neelam Sen, Fan Zhang, Swati Gaikwad, other members of our laboratories, Nick Guydosh, and Tom Dever for helpful comments and suggestions. This work was supported in part by the Intramural Research Program of the National Institutes of Health.

Additional information {#s5}
======================

Reviewing editor, *eLife*.

No competing interests declared.

Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft.

Data curation, Formal analysis, Investigation, Writing - review and editing.

Conceptualization, Formal analysis, Supervision, Project administration, Writing - review and editing.

Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing.

Additional files {#s6}
================

Data availability {#s7}
=================

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 9 and 9-supplement 1.

10.7554/eLife.58243.sa1

Decision letter

Sonenberg

Nahum

Reviewing Editor

McGill University

Canada

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

\[Editors\' note: this paper was reviewed by [Review Commons](https://www.reviewcommons.org/).\]

**Acceptance summary:**

The authors present convincing evidence that the interactions of eIF4A and eIF4E with Ded1 are critical in vivo in yeast. They delineated the locations in Ded1 of the binding sites for eIF4A and eIF4E. They provided strong evidence for the function of Ded1 in promoting translation in vivo and in vitro in a purified system. This study raises the interesting question as to why the mammalian Ded1 homolog, DDX3X is involved in many functions other than translation in the cell, such as miRNA biogenesis, mRNA nucleo-cytoplasmic transport, pre-mRNA splicing, and others, while in yeast it functions strictly in translation.
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Author response

> Reviewer \#1 (Evidence, reproducibility and clarity):
>
> The manuscript by Gulay et al. describes a study into the role of contacts between the RNA helicase Ded1 and components of the translation initiation factor 4F complex during eukaryotic protein synthesis. Using the purified yeast factors and targeted mutagenesis, the authors delineate binding sites for eIF4E and eIF4A in the Ded1 N-terminal domain. They then study the importance of these binding sites for growth and translation initiation in yeast in vivo, and in a reconstituted in vitro system, showing that both sites enhance the functioning of Ded1 during translation initiation, with subtly different effects.
>
> In my view the study is overall expertly done and relies on a broad portfolio of techniques that explores the importance of the two binding sites from a variety of angles. I think the discussion and the conclusions drawn are quite conservative and certainly do not overinterpret the data, however I see it as a downside that the discussion so strictly adheres to a static view of a fully formed eIF4F complex as the substrate for Ded1 binding, as exemplified by the scheme in Figure 9C. On a number of counts, the authors\' data suggest a much more flexible process, and a discussion that reflects this could enhance the manuscript. The first four points below make specific suggestions around which this could be based.
>
> 1\) Figure 5 suggests that mutations in the eIF4E binding site reduce interaction with eIF4E without reducing the interaction with eIF4G. Since the eIF4E:eIF4G interaction is very stable, this makes it unlikely that Ded1 interacts with a fully formed eIF4F complex (otherwise the pull-down of eIF4G should also be affected). Moreover, Ded1 was never detected in the initial cap-pull downs which led to the characterisation of eIF4F, again arguing that its interaction may be restricted to particular times or states of the initiation machinery.

This is a good point and we have revised the text to include the possible interpretation that Ded1 can interact separately with the individual subunits of eIF4F in addition to the intact complex. However, this would be odds with the expectation that the majority of Ded1 is associated with eIF4F in cells, based on estimates of the binding constant for Ded1 association with eIF4F and the cellular concentrations of these factors (Gao et al., 2016). Rather, it seems plausible that weakening the association of Ded1 with eIF4E would lead to a specific reduction in eIF4E coimmunoprecipitation with *Ded1-myc* owing to dissociation of eIF4E from eIF4G during the extensive washing steps involved in the experiment, notwithstanding the stable interaction of eIF4E with eIF4G. The absence of Ded1 in the initial cap pull-down experiments that recovered eIF4F can be explained by the known high off-rate of Ded1 from eIF4F (Gao et al., 2016).

> 2\) The authors\' data contain some evidence for regulatory interactions within Ded1. First, deletion of the CTD appears to enhance eIF4A binding but reduce eIF4E binding (Figure 1C). I note that the magnitude of the increase in eIF4A binding is similar to the decrease in eIF4E binding, yet the authors describe the first as \"comparable\" but the second as \"reduced\" -- it would be useful to see statistics here.

We had indeed neglected to add the statistics to Figures 1C-D, which we rectified by revising these panels of Figure 1. While the reduction in Ded1 binding to GST-eIF4E is significantly reduced for the Ded1-ΔC variant (P=0.03); the apparent increase in Ded1-ΔC binding to GST-eIF4A is not significant (P=0.10), which underlies our conclusion that *ΔC* impairs binding to eIF4E but not eIF4A.

> Second, I note that the 14-20 mutant appears to suppress the ded1-ts slow growth phenotype (Figure 3B, lane 3 at 34C) and also shows a slight increase in eIF4E binding (Figure 2C).

We find that this apparent suppression was not evident in several independent transformants and added this information to the text.

The apparent increase in binding of Ded1 variant 14-20 to GST-eIF4E is not significant (P=0.08).

> 3\) Figure 8C suggests distinct effects of Ded1 binding to eIF4A (important for translating transcripts with both cap-proximal and cap-distal stem loops) and eIF4E (only important for transcripts with cap-distal stem loops). This is not consistent with the model in Figure 9C, where the different interactions only contribute additive binding contacts with eIF4F.

Figure 8C shows that impairing Ded1 binding to either eIF4E (with Ded1-59-65/83-89 substitutions) or eIF4A (with 21-27/51-57 substitutions) significantly impairs translation of both cap-proximal and cap-distal SL reporters, just to a lesser extent for the cap-proximal reporter on weakening eIF4E-Ded1 interaction with Ded1-59-65/83-89. This difference in magnitude of the translation defects is consistent with our model in Figure 9C if we stipulate that impairing the Ded1-eIF4E interaction by the 59-65/83-89 substitutions has a smaller impact on assembly of the eIF4F-Ded1 complex compared to that conferred by the Ded1 21-27/51-57 substitutions and that robust translation of the cap-proximal SL reporter is more dependent on eIF4F-Ded1 association compared to the cap-distal reporter. Text to this effect has been added to the discussion of the model in Figure 9.

> 4\) The distinction between effects on attachment of Ded1 to eIF4F vs helicase activity is only superficially discussed. Figure 9A and B show that both eIF4E and eIF4A are important for attachment of Ded1 to eIF4F (as both binding mutants affect the K~1/2~), but only eIF4A is important for stem loop unwinding (as only the eIF4A binding site affects the K~max~). This is discussed by the authors. I think the fact that on an unstructured stem loop both binding site mutants still affect the K~1/2~ but not the K~max~ further supports this -- presumably this means that the Ded1/eIF4F interaction is always more efficient when supported by the additional eIF contacts, whereas Ded1 helicase activity is sufficient on its own on unfolded constructs but requires support from eIF4A on stem-loop containing transcripts.

We thank the reviewer for this insight, and we have added new Figure 9C and explanatory text to represent this interpretation.

> 5\) A last point where clarification would be useful is on the polysome profiles in Figure 8. Translation initiation defects often lead to the appearance of a shoulder on the monosome peak, which is usually interpreted as mRNAs with one translating ribosome and initiating 40S subunit (e.g.PMID 12471154 uses this extensively). None of the profiles shown in this study show such a shoulder, can the authors explain why this is?

The absence of halfmers can be explained if reducing Ded1 function by impairing its association with eIF4F primarily reduces attachment of PICs to the mRNA or impedes the migration of scanning PICs to the AUG codon for assembly of stable 48S PICs (with Met-tRNA~i~ base paired to AUG) that can withstand the hydrostatic pressures of sedimentation through sucrose. Indeed, our recent 40S profiling of *ded1* mutants indicates the occurrence of both such defects in PIC attachment and scanning.

> Moreover, although the polysome parts of the profiles clearly decay for the new ded1 mutants, the 80S peak does not seem to increase proportionally especially in the 59-65/83-89 mutant. Based on the \"mRNP\" peak which should be a useful internal standard for the numbers of cells lysed, this mutant seems to have lost most of its ribosome content.

We appreciate the point, but don't think that the proportion of total A~260~ present in the free mRNP peak can be assumed to be constant between WT and *ded1* mutants in which the proportion of mRNA in mRNPs might well increase as the result of reduced polysome assembly.

> Lastly, I\'m surprised that the ded1-ts mutant on its own seems to have virtually no effect on translation even at the restrictive temperature of 36C which the legend to Figure 8 indicates was used here (cf. Figure 8A and Figure 8---figure supplement 2).

It cannot be said from the data in Figure 8A that the *ded1-ts* mutation has no impact on polysome assembly because the WT *DED1* profile isn't shown here. However, we had analyzed isogenic *DED1^+^* cells in parallel and found, as expected, a significantly greater P/M ratio (3.90 +/- 0.11) compared to that shown in the figure for *ded1-ts* (2.39 +/- 0.10). This information has been added to the Figure 8A legend.

> Reviewer \#1 (Significance):
>
> The work adds significant conceptual detail to our understanding of the role of Ded1 in translation initiation. On the path to understanding the mechanism of translation in any detail, this is essential work. Thanks to the thorough and methodologically broad approach used, the work strongly enhances our understanding of a central biological process, and since the interaction sites are highly conserved throughout eukaryotes, the work done here in yeast informs our understanding of general eukaryotic biology. Like any good study that forays into new territory, the work raises as many questions as it answers -- one immediate one being questions around the order of events during complex formation in vivo as well as regulation of events during complex assembly. With alterations to the discussion based on my points above, I think this side would be presented more clearly. There is a strong history of fundamental studies into translation factors influencing and informing important fields including cancer (e.g. PMID 28653885) and other diseases (30038383, 30290184) and understanding fundamental translation factor biology is also becoming important for manipulating translation in bioprocessing and synthetic biology (27760840, 30615942). Thus, I have no doubt that the present study will be of interest to a wide readership.

As noted above, we altered the discussion based on several of the reviewer's points.

> Reviewer \#2 (Evidence, reproducibility and clarity):
>
> In this manuscript entitled \"Distinct interactions of eIF4A and eIF4E with RNA helicase Ded1 stimulate translation in vivo\", Gulay et al. identify separate amino acid clusters within the NTD of Ded1 required for interaction with eIF4E and eIF4A. They demonstrate that disruption of these clusters impairs cell growth, steady-state polysome levels and preferentially affects translation of an mRNA reporter with 5\' UTR structure versus one with no/less structure. Disrupting Ded1 NTD interactions with eIF4E or eIF4E affected kinetics of 48S assembly on a synthetic mRNA with cap-proximal structure.
>
> -- If possible, can the authors provide us with a sense of the type of affinities that Ded1 has for eIF4E and eIF4A?

Based on K~1/2~ values determined by Gao et al. from kinetic analysis of unwinding of a model substrate, the affinity of Ded1 for eIF4A was estimated to be in the range of 45-800 nM, depending on whether Ded1 or eIF4A are present alone (800 nM) or eIF4A is complexed with RNA (45 nM) (Gao et al., 2016). Unfortunately, we have no estimate for the affinity of Ded1 for eIF4E.

> -- Figure 3D -- there appears to be two bands for Ded1. Can the authors comment on these?

Unfortunately, we cannot comment definitively on this point.

> It looks like in lane 8, there is reduced expression of D2-90 compared to the mutants in lanes 6 and 7. Perhaps quantification from several gels can be provided under the panel.

We added to Figure 3D the requested quantification of the Ded1/Hcr1 ratios determined from multiple replicates, and indicated in the legend to Figure 3D that the particular replicate shown here was atypical in suggesting a reduced level of the *ded1-ts-Δ2-90* product vs. the parental *ded1-ts* product.

> -- Figure 6. How would the 4E binding mutants behave in this assay?

We had examined this previously and found no effect of eIF4A overexpression on the growth defect of the *ded1-ts/59-65/83-89* allele, which is specifically defective for binding eIF4E. We have added this control observation in a new Supplementary figure to Figure 6 (Figure 6---figure supplement 1) and mentioned it in the text, which supports our interpretation of results in Figure 6B that eIF4A suppresses the growth defect of *ded1* alleles that are partially defective for binding eIF4A by restoring Ded1-eIF4A association through mass action.

> -- The sentence \"Hence it is conceivable that W88 and R27 mediate conserved interactions between Ded1 and its Ddx3 homologs in animals with eIF4E and eIF4A, respectively.\" is speculative. Please remove or rephrase to focus only on what is in the paper -- the yeast data.

We have removed the sentence.

> -- Figure 8. Why was the Cap-proximal SL reporter used in D, rather than the cap-distal SL which showed a greater effect in panel C? Do the authors have data for the cap-distal SL.

In panel C, both reporters showed a marked reduction in expression for the two mutants impaired for binding eIF4A or eIF4E analyzed in panel D. Unfortunately, we don't have data for the cap-distal SL reporter for the experiment in panel D, which is very labor-intensive.

> -- Figure 9. The nomenclature used for the mutants is different than what is used in the rest of the figures. Also, the numbers don\'t align properly with the columns in Panels A and B.

These small errors in the figure have been fixed.

> -- Figure 9 A, B. Can the authors provide the raw data for the results leading to the data in Panels A and B? Perhaps as a supplemental Figure.

This source data has been provided as a supplementary excel file.

> Reviewer \#3 (Evidence, reproducibility and clarity):
>
> Summary:
>
> This manuscript by Gulay, et al. focuses on the function of Ded1, a DEAD-box RNA helicase, in translation initiation, specifically its interaction with the eIF4F translation complex. The authors identify small mutations in Ded1 that affect its interactions with eIF4A and eIF4E, and they utilize these mutants to examine the importance of the interactions for cell growth and translation in budding yeast using previously established in vivo and in vitro techniques. For the most part, the data and conclusions of the manuscript are solid; however, there are a few points at which further control experiments would be helpful and/or opportunities were missed to increase confidence in the results. There are also a few issues with interpretation/discussion that should be addressed.
>
> Major comments:
>
> 1\) In Figure 2, have the authors considered whether there might be competition for 4A and 4E binding to Ded1? This would not be consistent with their overall model, but it would explain the effects on 4A binding in the 51-57 mutant vs. 51-57/59-65 mutant. A competition binding experiment could reasonably be done with recombinant proteins in hand.

Such competition is not possible in this experiment as only GST-eIF4A or GST-eIF4E are present in the binding reactions.

> 2\) In Figure 2---figure supplement 4, the single point mutants should be tested for effects on binding of both 4A and 4E as controls. This is especially relevant for the mutants in the 51-65 region that appear to have cross-antagonistic effects (point 1).

We have determined that R27A, which impairs binding to GST-eIF4A, does not affect binding to GST-eIF4E, as expected from the fact that the 21-27 substitution

(encompassing R27A) specifically impairs interaction with GST-eIF4A (Figure 2B-C). We had also determined that R51A does not impair binding to GST-eIF4E and that R83A does not affect binding to GST-eIF4A, indicating that neither of these Ded1 substitutions affect either interaction. These additional results have been added to Figure 2---figure supplement 4. While we have not tested the Y65A and W88A substitutions for their effects on binding to GST-eIF4A, it seems highly unlikely that they would impair this interaction considering that the 59-65 and 83-89 clustered Ala substitutions, which encompass Y65A and W88A, respectively, did not did so (Figure 2B).

> 3\) Along these same lines, the Y21A mutant should be tested for 4D binding and possibly other defects (4G, enzymatic defects) since it has no 4A binding defect but significant in vivo phenotypes.

As already shown in Figure 2C, the 21-27 clustered Ala substitution, which encompasses Y21A, did not affect binding to GST-eIF4E, making it highly unlikely that Y21A would do so. We feel that understanding the molecular basis of the growth defect conferred by the Y65A substitution is outside the scope of this report.

> 4\) The rationalization for the focus from Figure 3 on in using ded1-ts as a sensitized background is not very well-described. The mutants by themselves seem to have phenotypes (e.g. Figure 3C), why not use these without the possibly confounding effects of another mutation?

When we began the study, we weren't sure if mutations specifically impairing either eIF4E or eIF4A would have a marked phenotype on their own, noting that deletion of the Ded1 CTD that eliminates the eIF4G binding site has no effect on cell growth in otherwise WT cells. Hence, we chose the standard genetic practice of using a sensitive background and evaluating synthetic phenotypes in combination with *ded1-ts*.

> Along these same lines, the polysome profile of the ded1-ts control strain in Figure 8A is surprisingly normal (higher P/M than the DED1 strain in Figure 8---figure supplement 3) given that this strain was previously shown to have a substantial defect under less restrictive conditions (Sen et al., 2015).

As noted above for reviewer 2, we had analyzed isogenic *DED1^+^* cells in parallel and found, as expected, a significantly greater P/M ratio (3.90 +/- 0.11) compared to that shown in the figure for *ded1-ts* (2.39 +/- 0.10). This information has been added to the Figure 8A legend.

> 5\) The suppression experiments in Figures 6 and 7 are good genetic evidence. However, the authors\' interpretation of the 21-27/51-57 double mutant does not seem to fit the data, since the interpretation relies on a complete ablation of 4A binding, while this mutant still appears to interact at a reduced level in vitro and in vivo.

We disagree that it can be concluded that the Ded1 21-27/51-57 double mutant retains residual binding to eIF4A, as the difference in binding to GST-eIF4A between this variant and complete deletion of the Ded1 NTD (ΔN) in Figure 2B is not statistically significant. In addition, the residual CoIP of eIF4A with the myc-tagged Ded1 harboring 21-27/51-57 could easily be mediated by eIF4G, whose coimmunoprecipitation is unaffected by these NTD substitutions.

> Further, an additional control needed in Figure 6 is to express hcTIF1 in the 4E binding mutant (59-65/83-89) -- if the authors are correct, it should not rescue growth. Also, have the authors attempted hcDED1 in a TIF1/TIF2 mutant? That would complement the other suppression experiments nicely. Finally, do the suppressions also rescue polysome and/or scanning defects as in Figure 8?

As mentioned above for reviewer 2, the predicted result was obtained as hc*TIF1* does not suppress the growth defect of the 59-65/83-89 double mutation, and has been included in a new supplementary figure (Figure 6---figure supplement 1). We were unsure of the reviewer's objective in asking us to test for suppression of a *TIF1/TIF2* mutant by hc*DED1,* and unclear about what mutant should be examined. A new supplementary figure (Figure 8---figure supplement 5) and explanatory text has been added providing evidence that hc*TIF1* mitigates the reduction in *LUC* reporter expression conferred by the *ts/21* mutation (that allows residual eIF4A/Ded1 interaction) but not by the *ts/21,51* mutation (that abolishes eIF4A interaction), nor by the *ts/59,83* mutation that impairs eIF4E interaction (included as a negative control). Rescue by hc*CDC33* was not attempted because eIF4E overexpression confers a slow-growth phenotype, which is why we reverted to overexpression of Ded1 in the *cdc33-1* mutant in the genetic analysis of Figure 7.

> 6\) The manuscript relies heavily on genetic arguments, but some caution is warranted, given that these arguments are often somewhat indirect. This is especially true given that no attempt is described at making mutations in 4A and 4E that do not interact with Ded1. I do not think constructing such mutants is required, but they should temper their conclusions and offer caveats throughout, especially when discussing the model in Figure 9C.

A statement has been added to the Discussion that, while it is impossible to rule out additional effects of the *ded1* mutations beyond impairing Ded1 interaction with eIF4A or eIF4E, the genetic suppression experiments in Figures 6-7 provide strong evidence in favor of this interpretation.

> 7\) In regard to the model, the authors claim that the 4A interaction may be \"more important\" than the 4E one, largely based on the in vitro translation assays in Figure 9. However, only the single (59-65) 4E-binding mutant was used in these assays compared to the double (21-27/51-57) 4A-binding mutant. Either the 51-57/83-89 double mutant should be tested, or the authors need to modify their claim about the relative importance of binding to the two factors.

We agree and have modified our claim accordingly in the Discussion.

> Minor comments:
>
> 1\) The focus on how the 4A/4E mutants \"exacerbate\" defects caused by deletion of the CTD is a fairly weak point. The effects seem largely additive rather than necessarily illustrating a major aspect of the interaction with eIF4F. I would recommend moving Figure 4, for instance, to the supplement and somewhat reducing the prominence of commentary about the CTD in the manuscript. Additionally, it is not completely accurate that no studies have shown an in vivo effect of the Ded1-CTD and/or the Ded1-eIF4G interaction -- Hilliker et al. showed some in vivo effects of the CTD deletion, Senissar et al. showed genetic interactions on growth with ded1 mutants and eIF4G, and Aryanpur et al., 2019, recently showed a significant in vivo effect of the CTD, linked to eIF4G interaction, in certain conditions.

We prefer to leave Figure 4 in its current position because we consider it significant that the deletion of the Ded1 CTD confers a growth defect only in the presence of the Ded1 NTD mutations that impair eIF4E or eIF4A binding, ie. we observe synthetic growth phenotypes between these NTD and *ΔC* mutations. This provides important evidence for additive effects of separate Ded1 interactions with eIF4A, eIF4E and eIF4G in assembly of an eIF4F·Ded1 complex that enhances Ded1 stimulation of translation. However, we have revised the Discussion to better explain the significance of this synthetic genetic interaction.

Re-examining the literature cited by the reviewer did not reveal any published findings that contradict our conclusion that the in vivo importance of the Ded1 CTD in stimulating translation at native levels of Ded1 expression has been unclear. Hilliker et al., 2011, observed a slight exacerbation of the Cs^-^ phenotype of a double NTD mutation in combination with a deletion that spans the boundary between the core helicase and CTE of Ded1; and they found that a deletion in the CTD impairs Ded1 stimulation of translation in vitro, but it had no effect on cell growth even at low temperature where defects in Ded1 function are most readily observed. Senissar et al., 2014, examined no mutations in the Ded1 CTD. Aryanpur et al., 2019, recently uncovered an interesting role for the Ded1-CTD in TORC1-mediated down-regulation of translation initiation (rather than stimulation) during nutrient starvation. We have revised the Discussion to more thoroughly discuss our findings on the CTD in relation to these published findings.

> 2\) The strain background used in the pull-downs in Figure 5 is described differently in the text compared to the figure legend and Table 2. First, tagged TIF4631 appears to be expressed from a plasmid, not from the eIF4G2 promoter. Second, was wild-type Ded1 present in these cells? If so, its presence in the pull-downs could be confounding in interpreting the results.

The strain descriptions are consistent throughout, but we have added explanatory information in the Results and Table indicating that the strain contains deletions of *TIF4631* and *TIF4632* and contains *TIF4631-HA* on a plasmid under the control of the *TIF4632* promoter and transcription terminator, as described previously by Tarun and Sachs. We have also added text indicating that the presence of WT *DED1* in the strain could be intensifying the effects of the mutations in the myc-tagged *ded1* alleles on association with eIF4F components by competition for binding the latter.

> 3\) In a number of the Western blots, the protein levels in the exposures shown are fairly saturated and do not appear to be in a linear range (e.g. Figure 6C). It is difficult to be sure the expression levels are actually similar if this is the case.

As noted above for reviewer 2, we have added quantification of Ded1 protein levels from multiple replicates to Figure 3D. For Figure 4B, there is no question that the Ded1 variants containing the point mutations are expressed as well or better than the parental WT or *ΔC* proteins, establishing the key objective of the Western analysis. For Figure 6C, the main purpose of the analysis was to confirm that eIF4A is comparably overexpressed in the key *ts/21-27/51-57* mutant (lane 12) versus the other mutants (lanes 2, 4, 6, 8, 10), which we feel was achieved, noting that the eIF4A signals are invariably greater in the hc*TIF1* vs. vector transformants.

> 4\) In Figure 8C, the ded1-ts presumably already has defects compared to wild-type cells, especially in the stem-loop reporters. The authors should probably document these defects somewhere, even if they also show the relative differences as in Figure 8C. Along similar lines, in Figure 8---figure supplement 1, why are the ded1-ts values not all set to 1.0 like in Figure 8C? The legend indicates they should be the same as Figure 8C.

The defects in reporter expression conferred by *ded1-ts* are indicated in Figure 8---figure supplement 1, which has been cited explicitly in the Results; and the legend to Figure 8---figure supplement 1 has been modified to indicate that the results for the two SL reporters in the parental *ded1-ts* strain were not normalized to 1.0 in the manner conducted in Figure 8C.

> 5\) Also regarding Figure 8C, the authors do not offer any interpretation of why the cap-proximal and cap-distal stem-loops are differentially affected by the different mutants. Why might this be?

As noted above for reviewer 1, we will add text to the Discussion regarding this point.

> 6\) In Figure 8D, there does not appear to be any statistical analysis as to whether the observed changes are significant.

We have added a new supplementary figure (Figure 8---figure supplement 4) with evidence indicating statistically significant reductions in the proportions of the *FLUC* SL reporter found in heavy polysomes for both *ded1* alleles harboring substitutions in the NTD vs. the parental *ded1-ts* allele.

> Reviewer \#3 (Significance):
>
> This work advances our understanding of the mechanism of translation initiation, specifically the interactions of an RNA helicase, Ded1, that is known to be important in initiation, although its function has not been fully described. This study builds on previous work by this group and others (e.g. Hilliker et al., 2011; Senissar et al., 2014; Sen et al., 2015; Gao et al., 2016; Gupta et al., 2018) to better define the relationship of Ded1 and the eIF4F complex. As such, this work will be of significance to those in the translation field, particularly those studying initiation factors and/or RNA helicases. I expect that the identification of Ded1 binding determinants for eIF4A and eIF4E will be of marked interest for researchers studying these factors specifically. On a broad level, however, the research presented does not propose especially novel hypotheses or mechanisms and uses well-established techniques, so it is not likely to be appropriate for a high impact journal. This work is more of a \"fill in the details\" study, but it is solid work and should be published, pending the ability to address reviewer comments.

We respectfully disagree that this work merely "fills in details" as there was previously no compelling evidence that the individual interactions of eIF4A or eIF4E with Ded1 are important in vivo, nor that they are even more crucial when the Ded1CTD interaction with eIF4G is compromised. As such, the results provide the first strong evidence that robust Ded1 function in living cells is dependent on its association with the eIF4F complex, including separate contacts with each of its three subunits. Accomplishing this required a combination of genetics and biochemistry to map the locations of the distinct binding sites for eIF4A and eIF4E in the Ded1 NTD to the amino acid level, establish their importance for Ded1's ability to enhance bulk and mRNA-specific translation in vivo and to stimulate 48S PIC assembly in a fully purified system; and also to demonstrate by suppressor analysis that the translation defects in vivo indeed arise from impaired association with eIF4A or eIF4E.
